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ABSTRACT 
Alzheimer's disease is the most common form of senile dementia, 
though its cause is unknown. Of the six principal hypothesised 
origins of the disease, two were examined experimentally. 
The cholinergic hypothesis proposes that Alzheimer's disease 
is caused by neuropathological damage to the nucleus basalis 
of Meynert (nbM), causing a subsequent global reduction in brain 
acetylcholine levels, which results in the observed loss of recent 
memory and subsequent behavioural symptomatology. To test this 
hypothesis, rats were injected with either 0.01, 0.03 or 0.06 
mg/kg scopolamine hydrobromide (a cholinergic muscarinic blocker) 
and tested on a non-spatial task of object recognition, nonmatching-
to-sample. The highest dose of scopolamine produced a significant 
impairment on a retention interval of 60 sec on the task, but 
there was no evidence that the drug produced faster forgetting 
of the stimuli. The result suggests that the drug caused a general 
depression in performance which may or may not reflect amnesic 
properties. In contrast, simultaneous tests with the acetyl-
cholinesterase, physostigmine, indicated that increasing available 
acetylcholine might attenuate the effects of the retention interval. 
A series of control tests revealed that scopolamine and physo-
stigmine had no effect on the motor activity of the animals. 
A second series of control tests indicated that the rats relied 
on cues from a variety of sensory modalities in order to perform 
the nonmatching task. The notion that a cholinergic dysfunction 
is sufficient to produce the symptoms of Alzheimer's disease 
is questioned. It is proposed that structural damage (perhaps 
to the limbic system) may be a more likely cause of this disease, 
rather than a specific cholinergic abnormality. 
The second part of this thesis examined the toxin hypothesis 
of Alzheimer's disease, which proposes that the disease is caused 
by the accumulation of aluminium in the brain. Accordingly, 
rats were administered 72 mg/kg aluminium hydroxide orally, for 
three months, and recent memory capacities were assessed over 
20 and 40 sec retention intervals on the nonmatching-to-sample 
task. No effects of aluminium administration on memory were 
noted. Additionally, aluminium did not appear to have any effect 
on the motor activity of the rats, and no accumulations of aluminium 
were detected in the nbM, hippocampus, amygdala or neocortex 
of the animals. Various reasons for the failure to find either 
accumulations of aluminium in the brain or recent memory effects 
are outlined. 
Finally, the AF64A-treated animal is considered as an 
alternative to the scopolamine-treated animal model, and other 
possible causes of Alzheimer's disease are discussed -notably 
the genetic hypothesis; and the possibility that a combination 
of accumulations of brain aluminium with decreases in CAT levels 
may be responsible for the disease. 
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CHAPTER ONE. INTRODUCTION. 
1.1.1. Alzhe1mer's U1sease and its Diagnosis. 
Alzheimer's disease is the most common form of senile dementia, 
with an estimated over one million affected individuals in the U.S.A. 
(Whitehouse et al., 1982). Three stages in the clinical course of 
this illness have been described (Pearce, 1984). 
Stage 1 is characterised by amnesia, disturbances of spatial 
orientation and lack of spontaneity. This lasts for 2 - 4 years and 
then merges into the second stage. 
Stage 2 is characterised by a progressive dementia involving 
many aspects of higher mental function, but is accompanied by focal 
features. These consist of agnosia, apraxia and dysphasic disturb-
ances and may be accompanied by hypertonic and akinetic disturbances 
of motor activity. 
Stage 3. In the final stage the patient shows complete dementia, 
often epileptic seizures, and may have features of the Kluver-Bucy 
syndrome. At this stage the patient is withdrawn, incontinent, and 
largely dependant on others in respect of even the simplest necess-
ities of life. 
This pattern of abnormalities is not, however, unique to 
Alzheimer's disease, and so cannot be used as the sole basis for 
diagnosing the illness. For instance, the clinical features of Pick's 
disease are usually impossible to differentiate from Alzheimer's 
disease. The difference between the two illnesses lies in their 
pathology: Alzheimer's disease is characterised by diffuse cerebral 
atrophy (see P.2 ), whereas in Pick's disease the atrophy is sharply 
demarcated and largely restricted to the anterior portions of the 
frontal and temporal lobes. Hence, Alzheimer's disease can only be 
distinguished from Pick's disease with certainty by pathological 
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examination, such as brain biopsy. Recent advances in radiological 
techniques such as the Computerised Tomography Scan and Positron 
Emission Tomography are encouraging, however, as these techniques 
yield high diagnostic accuracy in the assessment of (respectively) 
the degree and distribution of brain atrophy, and decreases in meta-
bolic activity, in various forms of senile dementia. Thus it may 
soon be possible to diagnose Alzheimer's disease without having to 
rely on autopsy or biopsy data. 
The duration of Alzheimer's disease is variable, commonly 
between 5 and 10 years, but in certain instances it may be consid-
erably longer. The age of onset of the illness also varies consid-
erably, and for many years two distinct types of the disease were 
distinguished; presenile dementia (classical Alzheimer's disease) 
in which the clinical symptoms could be evident from the age of 45, 
and senile dementia of the Alzheimer type, which applied to people 
first exhibiting the symptoms of the disease after the age of 65. 
It is now generally recognised that the two are functionally the 
same disease, though there is a tendency for them still to be treated 
as two separate entities in the literature. 
Autopsy reveals highly characteristic pathological and neuro-
chemical changes in the brain of individuals who have suffered from 
Alzheimer's disease. The pathological features consist of diffuse 
degeneration of the neocortex, this being most severe in the temporal, 
parietal and occipital lobes. The posterior cingulate gyrus, amygdala, 
hippocampus and hypothalamus are also involved, though the anterior 
cingulate gyrus, caudate nucleus, thalamus and mamillary bodies are 
affected only minimally. Neurofibrillary tangles (intracellular 
bundles of paired helical filaments that fill the perikaryal cyto-
plasm surrounding a normal nucleus) are found in degenerating neurons 
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1n the neocortex, hippocampus, amygdala and brain stem. Senile 
plaques (extracellular clusters of abnormal cell processes in which 
a central mass of amyloid, a protein, is surrounded by unmyelinated 
neurites) are found predominantly in the grey matter of the cortex. 
Plaque formation in areas such as the hippocampus and amygdala occurs 
at an early stage in Alzheimer's disease, but is also extensive in 
non-demented elderly people. Senile plaques are sometimes found in 
the caudate nucleus, putamen, thalamus and mamillary bodies, and in 
the brain stem, cerebellum and diencephalon in advanced cases of the 
disease. In these regions, however, plaques never acquire the density 
seen in cortical regions. Since plaque and tangle formation is most 
extensive in the cortex, this region has received the most intensive 
investigation. At first sight it would seem reasonable to associate 
the brain atrophy, nerve cell degeneration and the plaques and tangles 
with the clinically observed dementia and focal signs of the disease, 
but although there is some evidence to support this (see P.17 ), 
the association is by no means established as fact. 
The neurochemistry of Alzheimer-type dementia is related to the 
involvement of different neurotransmitter and neuropeptide systems 
which exist in the brain. The significant loss of neurons from 
regions at the base of the forebrain consequently reduces the amount 
of neurotransmitters, notably acetylcholine, normally released from 
the terminals of those neurons in higher brain centres. Consistent 
biochemical changes in postmortem tissue are also seen (but to a 
lesser extent) in the noradrenergic, serotonergic and somatostatin 
systems. The cholinergic abnormality in particular appears to be 
closely related to cognitive impairment, although the precise nature 
of this relationship has yet to be determined. 
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1.1.2. Prevalence. 
Attempts to establish the prevalence of Alzheimer's disease are 
problematic for two reasons. Firstly, problems arising in the diag-
nosis of the disease (see 1.1.1.) mean that the figures regarding 
the occurence of the disease in total terms will be sparse, and at 
best only estimates. Secondly, the distinction between Alzheimer's 
disease and senile dementia of the Alzheimer type (seeP. 2 ), while 
no longer widely accepted, is nevertheless reflected in the figures 
quoted for the prevalence of this illness. 
For example, Gordon and Sim (1967) recorded 80 cases of presenile 
dementia. The final diagnosis in these 80 patients was Alzheimer's 
disease in 48 (60%) and Creutzfeldt-Jakob disease, Pick's disease 
and 'others' collectively represented in 32 (40%). Thus Alzheimer's 
disease is the likeliest diagnosis in a patient with presenile 
dementia. 
A representative series of 68 cases described by Sourander and 
Sjogren (1970) showed the age of onset as follows: 
Age 45 
Age 60 
59 in 50% of cases 
64 in 30% of cases 
Age 65 - 69 in 20% of cases 
This indicates the distribution in the classic presenile dementia, 
but since senile dementia is almost certainly the same disorder, the 
figures do not represent the total picture of Alzheimer's disease and 
they underestimate the high incidence in patients over 70 years of 
age. 
In Britain, extensive studies of the population over the age of 
65 have been carried out in Newcastle Upon Tyne. Kay et al. (1964) 
found a total prevalence of about 5% for cases of severe mental deter-
4 
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-'10 cases of mild mental de lee-
ioration, and a total prevalence of 10% for dementing illnesses of 
all degrees of severity. 
Kay et al. (1970) continued the Newcastle work by examining a 
further sample of elderly subjects in that city. When the data were 
pooled with those from the previous investigation (Kay et al., 1964) 
they were able to estimate prevalence rates for "chronic brain synd-
romes'' for different age groups within the senile range. These are 
shown in Table 1.1 .. It can be seen that the proportion of the popul-
ation judged to be demented increases with age, and that there is a 
dramatic increase in prevalence once the age o!· 80 is exceeded. The 
overall prevalence rate given by Kay et al. (1970) for the over 65's 
is 6.2%, lower than the 10% given in the earlier Newcastle study. 
This is probably due to the later report adopting a more stringent 
set of diagnostic criteria for dementia. 
Finally, Larsson et al. (1963) estimated that the lifetime risk 
of contracting senile dementia is 1.8% in males and 2.1% in females. 
The higher risk in females is at least partly, if not entirely, due 
to their tendency to live to a greater age than males, when dementia 
becomes more prevalent. 
It should be noted that there have been no new major surveys of 
dementia for some time, so the figures quoted are derived from a 
previous generation of elderly people. This means that there is a 
possibility of small changes in the prevalence of those judged to be 
suffering from dementia since the studies quoted were undertaken. 
5 
I AGE I Years I PREVALENCE {%) I 
65 - 69 2.3 
70 - 74 2.8 
75 - 79 5.5 
80+ 22.0 
TOTAL 32.6 
Table 1.1. Prevalence of "chronic brain syndrome" in Newcastle 
Upon Tyne. 
(From Kay et al., 1970}. 
l.l.J. Why Alzhein1er·'s Disease is a Problem. 
Dementing illness inflicts a grave burden on patients, family 
and doctor. Dement1a, with its associated physical ill health and 
loss of mobility, can help to produce social isolation. In some 
cases, isolation could augment mental deterioration by leading to 
depression which, in turn, can produce self-neglect and dietary 
inadequacies. Therefore afflicted individuals make great demands 
upon medical and social support services. In the later stages of the 
disease, patients are bedridden; unable to speak, or take care of 
themselves. 
Kay et al. (1970) examined the load placed on various resid-
ential facilities by their sample of 449 elderly subjects. Of those 
with "chronic brain syndromes", 61% were admitted to an institution 
of some kind (hospital, local authority home, etc.) as compared with 
only 25% of those with functional psychiatric illnesses, and 19% of 
those considered to be psychiatrically normal. Not only were more 
patients with "chronic brain syndromes' 1 admitted, but their 
average length of stay was much longer. However, there is no known 
treatment for Alzheimer's disease and until there is, the burden of 
dementia for the patient, family, medical, social and welfare services, 
is likely to increase with increasing longevity. 
To transform Alzheimer's disease from a disease that can at 
present only be described to a disease that is understood and can be 
treated necessitates a thorough understanding of its aetiology. This 
is the fundamental problem of Alzheimer's disease - no-one knows 
what causes the disease or how its characteristic changes are 
brought about. From a vast array of experimental work, certain 
factors have however emerged which may contribute to the neuronal 
6 
degeneration an eso;ert Lidl and probably a fundamental part 
of Alzheimer's disease. These factors are discussed in the following 
sections. 
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1.2.1. Aetiology of Alzheimer's Disease. Hypotheses. 
Six hypotheses underlie most of the research on Alzheimer's 
disease and its causes. Although they are usually treated separately 
in the literature, they are not necessarily mutually exclusive. The 
Genetic, Viral, Abnormal Protein and Vascular hypotheses are described 
briefly below, while the Toxin and Acetylcholine hypotheses (since 
these form the basis of the experimental work of this thesis) are 
discussed in detail in Sections 1.3. and 1.4., and in Chapters two 
and three. 
1.2.2. Viral Hypothesis. 
The hypothesis that Alzheimer's disease may be caused by a 
virus arises from alleged similarities between this illness and 
Creutzfeldt-Jakob disease. 
Creutzfeldt-Jakob disease is a rare brain disease (one new case 
is discovered per million of population per year, Wurtman, 1985), 
which usually affects people between 55 and 75 years of age. It 
causes progressive dementia, disturbances in posture, vision and the 
control of movement. In these respects, Creutzfeldt-Jakob disease 
is very similar to Alzheimer's disease, with the exception that in 
the former, death comes only about a year after the onset of the 
disease. 
Neither disease causes brain inflammation or fever, yet it is 
known that Creutzfeldt-Jakob disease can be trans~itted to chimp-
anzees by the injection into the brain of extracts of infected tissue 
(Gibbs et al., 1968). This indicates that it must be caused by an 
infectious agent, presumably a virus. In Creutzfeldt-Jakob disease, 
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Cl long lncc;batiurt per· .iud \roughly one quarter of the affected indi v-
idual's normal life span) may pass between exposure to the agent and 
the first appearance of clinical signs. The infectious agent has 
thecefure been thought to be an unconventional, "slow" virus. 
Gajdusek et al. (1976) have observed an abnormal structure made 
up of twisted filaments in the brainsof people with Creutzfeldt-
Jakob disease. They have proposed that this filamentous structure 
may be the infectious agent causing this disorder, and also Alzheimer's 
disease. The structures are not present in Alzheimer's disease, but 
they do share some immunological properties with the amyloid fibrils 
of neurofibr1llary tangles. 
If Alzheimer's disease is caused by a virus, it should be 
transmissible, but attempts to transmit it to experimental animals 
have been unsuccessful. Infection by the agent of the disease may 
require a particular genetic make-up, a concurrent immune disorder, 
or prior exposure to an environmental toxin. 
1.2.3. Vascular Hypothesis. 
It has been recognised since the 1950's that there is a decrease 
in total hemisphere blood flow in dementia. For example, Ingvar 
(1968) found a reduction in hemisphere flow and in the relative 
amount of grey matter in senile and presenile dementia, the reduction 
being proportional to the degree of dementia. Simard et al. (1971) 
also observed reduced blood flow in both presenile and senile 
dementia. Scheibel and Scheibel (1975) found that small neurons 
controlling the dilation and contraction of brain arterioles tend to 
disappear with normal aging and are particularly deficient in the 
brain of demented patients. It was therefore proposed that the loss 
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uf nerves controlling blood flow prevents the del1very of enough 
blood to neurons, and that thi.s causes the extensive neuron death 
characteristic of Alzheimer's disease. 
While 1t is accepted that Alzheimer's disease is associated 
with a reduction in the amount of blood delivered to the brain (and 
consequently in the amount of oxygen and glucose extracted from this 
blood, and in the energy generated from the oxygen and glucose), it 
is unclear whether reduced blood flow is in fact the cause, or the 
consequence, of the neuronal death. While reduced blood flow would 
cause neuronal damage, it is also true that a decrease in the number 
of cells consuming oxygen and glucose would be expected to diminish 
the brain's demand for blood. Until the sequence of these alternatives 
is determined, the causal contribution of inadequate blood flow in 
Alzheimer's disease remains unproven. 
1.2.4. Abnormal Protein Hypothesis. 
Alzheimer's disease is clearly associated with abnormal protein 
structures. Its three major pathological signs are neurofibrillary 
tangles within neurons, the amyloid that surrounds and invades 
cerebral blood vessels, and amyloid-rich plaques that replace degen-
erating nerve terminals. Each of these signs reflects an accumulation 
of proteins not normally found in the brain. 
Glenner et al. (1973) have proposed a theory for the pathogenesis 
of Alzheimer's disease based on cerebrovascular amyloid. They 
suggest that "amyloidogenic" proteins in the blood of a patient may 
be converted, by an enzyme in cerebral blood vessels, into amyloid. 
The amyloid damages the vessels, causing the leakage into brain 
tissue of other blood proteins; these proteins are toxic to neurons 
10 
and acLivdL~ dn enzyme that converts neurofilaments 1nto paired 
helical filaments, which further damage the neurons. Eventually the 
damaged neurons, with their neurofibrillary tangles, are engulfed in 
neurit1c plaques. The number of plaques tends to correlate closely 
with the extent of dementia (Perry et al., 1978). 
This theory is unconvincing for a number of reasons. For 
example, it does not say what causes the conversion process of amyl-
oidogenic proteins into amyloid (perhaps the synthesis of abnormal 
proteins is directed by abnormal genes, or by an environmental 
toxin?). Also, the proteins may give rise to the observed loss of 
neurons not because thay are toxic to the neurons, but because they 
crowd the neurons physically. Furthermore, in addition to accumul-
ating the three principal types of abnormal proteins (neurofibrillary 
tangles, amyloid, and senile plaques), the brain of Alzheimer's 
disease patients seems to synthesise abnormal quantities of proteins 
in general (Wurtman, 1985). How or why the brain of demented 
patients should do this, is not explained by Glenner et al.'s (1973) 
theory. 
Finally, the question arises as to whether the protein accum-
ulations cause the disease, or whether they could be unrelated to 
whatever process destroys neurons, and be present only as an indicat-
ion that the destruction has taken place, i.e., as a consequence of 
the disease. 
1.2.5. Genetic Hypothesis. 
There are families in which the incidence of Alzheimer's disease 
is unusually high, and this constitutes strong evidence for the 
involvement of a heritable factor in at least some forms of the 
11 
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Families have been identified in which 10 or more members. 
representing four or five generations, have developed a dementia of 
the Al~heimer type. In such cases it appears that an aberrant gene 
is transmitted as an autosomal dominant (a gene that affects both 
sexes equally and that need only be inherited from one parent to 
have full effect). A genetic component can be indicated by large-
scale studies of family trees even in families in which the disease 
appears only sporadically. For example, Heston et al. (1981) either 
examined or obtained information about the parents, siblings and 
second-degree relatives of 125 patients, in different families, who 
died in Minnesota hospitals or nursing homes from 1952 to 1972, and 
showed adequate evidence at autopsy for a diagnosis of Alzheimer's 
disease. By 1981, 87 of the relatives had developed a dementing 
illness. In all autopsied cases that illness was diagnosed as 
Alzheimer's disease. 
In another study, Folstein and Breitner (1981) examined the 
role of genetic factors in cases they classified as being either mild 
or severe. Analysis of their data led them to conclude that there 
are two distinct forms of Alzheimer's disease; a relatively mild non-
familial form generally affecting very old people, and a genetically 
transmitted variant that accounts for about three-quarters of all 
cases. They calculate that for someone with an afflicted parent or 
sibling, the risk of developing the disease by the age of 80 is 
about 17%. 
Besides the epidemiological evidence, the genetic model is 
supported by the fact that nearly all people with Down•sSyndrome 
(Trisomy 21), a known genetic disorder, develop Alzheimer's disease 
by about the age of 40. The link between Alzheimer's disease and 
12 
~owr1's synorome has ~ecently been c1arifled by evidence that DNA 
markers on chromosome 21 are linked both to an abnormal protein gene, 
and to the autosomal dominant gene for Alzheimer's disease (Goldgaber 
et al., 1987; Tanzi et al., 1987; StGeorge-Hyslop et al., 1987; 
Selkoe et al., 1987). This evidence will be discussed in some depth 
in Chapter four. 
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1.3.1. Biochemical Alterations and Mechanisms of Cholinergic 
Transmission. 
Davis and Maloney (1976) and Bowen et al. (1976) reported the 
first clear biochemical abnormality associated with Alzheimer's 
disease. They found that the level of the enzyme choline 
acetyltransferase (CAT) can be reduced by as much as 90% in the 
hippocampus and cerebral cortex of Alzheimer disease patients. This 
enzyme catalyses the synthesis of the transmitter acetylcholine from 
its precursors, choline and acetyl coenzyme A. The loss of CAT 
activity reflects the loss of cholinergic, or acetylcholine 
releasing, nerve terminals in these two regions of the brain. The 
missing terminals are those of neurons whose cell bodies are in the 
basal forebrain or septum (see Diagram 1.1., which illustrates the 
major cholinergic pathways implicated in Alzheimer's disease). 
The dramatic biochemical disturbance first identified by Davis 
and Maloney (1976) and Bowen et al. (1976) has been confirmed repeat-
edly by other investigators (e.g., Perry et a1., 1977; Bowen and 
Davison, 1980; Carlsson et al., 1980; Sims et al., 1980), and seems 
to be the clue most likely eventually to point to the cause of 
Alzheimer's disease. 
Although a few studies have reported decreases in CAT activity 
in brains from non-demented (normal) elderly people (McGeer and 
McGeer, 1975; Davies and Verth, 1978), many more have failed to find 
any changes over a range of disease-free age groups (e.g., Bowen et 
al., 1976; Carlsson et al., 1980; Spokes, 1979). This suggests that 
the severe and consistent decrease found in Alzheimer's patients may 
reflect a disease-specific disturbance. 
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Cholinergic pathways innervating cortex. 
OCCIPITAL 
The cholinergic neuronal cell bodies of the basal forebrain located 
in the nucleus basalis of Meynert, the diagonal band of Broca, and 
the medial septal nucleus send axons that innervate the entire 
cortex including the frontal, parietal and occipital cortex, as well 
as the hippocampal formation. 
(From Coyle, Price and DeLong, 1983). 
Ma1:y ~LuJles have also been conducted to assess changes in CAT 
activity in aged animals. Although some studies comparing brains 
from rodents of different ages report reliable decreases in CAT 
activity, these changes are typically small (15 to 25%). Further, 
many studies have failed to find similar decreases (Strong et al., 
1980; Meek et al., 1977). Thus, most animal aging data agree with 
the general human literature, failing to demonstrate large or 
reliable decreases in the activity of CAT as a function of increased 
(normal) age. 
In order to understand the mechanism of cholinergic transmission, 
and the importance of CAT in this process, a brief description of 
the metabolism and movement of an acetylcholine molecule follows. 
The transmitter is manufactured primarily in the terminals from 
which it is released. The first step in its synthesis is the uptake 
of choline from the synaptic cleft. The choline can be taken up 
into the terminal by either of two transport proteins in the pre-
synaptic cell membrane. One of them is present not only on cholin-
ergic neurons, but also on all cells, since choline is required for 
the synthesis of phosphatidycholine (or lecithin), a consituent of 
all cell membranes. The other transport protein is found only on 
cholinergic terminals, where its particularly high affinity for 
choline enables the terminal to take up almost all the choline avail-
able in the synaptic cleft. 
The next step, catalysed by CAT, combines the choline with 
acetyl coenzyme A to make acetylcholine. Terminals have an excess 
of CAT and too little of the precursors choline and acetyl coenzyme 
A to keep the enzyme molecules fully occupied; the rate at which the 
transmitter is synthesised is therefore limited not by the amount of 
CAT enzyme but by the level of the two precursors (hence the proposal 
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that precursor loading may increase acetylcholine levels - see 
P. 27 ). Once synthesised, acetylcholine molecules are stored in 
the terminal until the arrival of a nerve impulse discharges some of 
into the synapse. Once it is in the synapse, an acetylcholine 
molecule can cross the cleft and interact with a receptor on the 
postsynaptic neuron, thereby transmitting the signal generated by 
the nerve impulse. It can be broken down by the enzyme acetylcholin-
esterase to generate choline, or it can interact with a receptor on 
the presynaptic membrane from where it came, thereby delivering a 
signal that modulates the subsequent release of acetylcholine 
from the presynaptic terminals. Diagram 1.2. summarises the metab-
olism and movement of an acetylcholine molecule. 
The principal receptor which triggers the postsynaptic response 
to released acetylcholine - the muscarinic receptor - is apparently 
normal in Alzheimer's disease - at least as far as can be judged from 
the levels of antagonist binding membranes in vitro (Perry et al., 
1977; Davies and Verth, 1978). So at the cellular level, the chol-
inergic defect of Alzheimer's disease appears to be related to 
changes on the presynaptic (rather than the postsynaptic) side of 
the cholinergic neurons, and most probably reflects degenerative 
changes in the cholinergic neuronal process (Pearce, 1984). 
The principal biochemical findings (to-date) in relation to 
cholinergic activities in autopsy and biopsy brain tissue are summ-
arised in Table 1.2.. That a large reduction in CAT is found, has 
already been mentioned. Additionally, in biopsy tissue, the rate of 
acetylcholine synthesis is markedly reduced (Sims et al., 1980), as 
is acetylcholinesterase (ACE). Anatomically, cholinergic abnormal-
ities measured biochemically are generally most marked in the cerebral 
cortex, although extensive reductions are also found in the amygdaloid 
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Figure 1.2. Trace of the metabolism and movement of an acetylcholine 
molecule. 
Choline (1) delivered to the synaptic cleft by the blood enters a 
presynaptic cholinergic terminal, where CAT combines it with acetyl 
coenzyme A (2) to form acetylcholine (3). When the arrival of a 
nerve impulse depolarises the neuron, acetylcholine is released (4). 
It can cross the synapse to interact with a receptor on the post-
synaptic neuron, thereby transmitting the signal generated by the 
nerve impulse (5). It can instead interact with a receptor on the 
presynaptic membrane (6), thereby modulating the further release of 
acetylcholine. Or it can be broken down by acetylcholinesterase 
(AChE) yielding choline (7), which is taken up by the terminal (8), 
or carried off in the blood (9). The break down of phosphatidylcholine 
(lecithin), a constituent of cell membranes, contributes to the 
choline supply (10). 
(From Wurtman, 1985). 
Transmitter 
precursor or 
metabolite 
Related 
enzymes 
Receptors 
( 
) 
ACTIVITY 
Acetylcholine 
Choline 
Choline acetyltransferase 
Acetylcholinesterase 
Muscarinic receptor binding 
Nicotinic receptor binding 
REPORTED FINDINGS 
Decreased level in autopsy 
tissue; decreased synthesis in 
biopsy tissue. 
Normal 
Reduction (50-90%) related to 
clinical and pathological 
features .. 
Reductions in biochemical and 
histochemical activities; some 
plaques and tangles positive 
histochemically. 
Normal. 
Unclear- reports vary- normal, 
reduced or increased. 
Table 1. 2. Cholinergic activities in Alzheimer's Disease (Cerebral Cortex). 
(From Pearce, 1984). 
nucleus, hippocampus, and in the basal nucleus of Meynert (Perry et 
al., 1982). 
1.3.2. Neurofibrillary Tangles and Senile Plaques. 
The significance of the two major Alzheimer-type neuropathol-
ogical abnormalities, neurofibrillary tangles and senile plaques, is 
not known precisely at present, though both appear to have a pathol-
ogical involvement in the dementing process (Perry et al., 1978). 
In the amygdala and hippocampus, the number of tangles tends to 
increase as a function of age, and in the entorhinal cortex of the 
hippocampal formation the number ~nd density of tangles is often 
used to distinguish normal, non-demented from demented (Alzheimer-
type) cases. Deficits of CAT have been linked to the degree of 
neurofibrillary change in Alzheimer's disease by White et al. (1977). 
Senile plaques are found predominantly in the grey matter of the 
cortex, and in the neocortex, hippocampus and amygdala. The relation-
ship of plaques to dementia is thought to be quantitative, based on 
the concentration or density of plaques. In most demented indiv-
iduals with Alzheimer's disease, plaque densities range from 15 to 
40 plaques per mm2 , and in clinically severe, neuropathologically 
advanced cases, may reach densities of 50 to 60 plaques per mm2 
(Pearce, 1984). 
The reduction in CAT levels has been shown to correlate with 
the number of senile plaques in the brains of patients with 
Alzheimer's disease (Perry et al., 1978). However, the precise 
relationship between the decrease in CAT levels from the cortex, 
hippocampus and amygdala and the increased occurrence of tangles and 
plaques in these same areas, has yet to be defined unequivocally. 
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1.3.3. Other Neurotransmitter Systems. 
The cholinergic system is not the only transmitter system 
involved in Alzheimer's disease, and in particular, consistent 
changes relating to another classical transmitter (nor-adrenaline) 
and one of the neuropeptides (somatostatin) have recently emerged. 
What is not clear, however, is whether these other changes are as 
closely linked to the disease process as changes in acetylcholine 
levels seem to be, or whether they may occur later as secondary-type 
changes. In this respect it would be useful to have information 
available on the sequence of changes occuring in the various neuro-
transmitter systems over the duration of the illness, although in 
any case the changes seen in the other systems are not as dramatic or 
as extensive as those seen in the cholinergic system. Research has 
focussed principally, therefore, on the possible link between 
Alzheimer's disease and deficits in the cholinergic system. 
1.3.4. Nucleus Basalis of Meynert. 
Comparisons between Alzheimer's patients and age matched controls 
reveal a severe loss of neurons in the basal nucleus of Meynert 
(nbM); a subcortical nucleus located within the substantia innominata. 
Because this brain area provides the primary cholinergic input to 
the cortical mantle these data offer the possibility that the 
decrease in cortical CAT in Alzheimer's patients may reflect a 
specific loss of cholinergic input to the cortex, with the nbM being 
the source of the damage. That this is the case is corroborated by 
Johnston et al. (1979), who demonstrated that lesions of the nbM in 
animals causes decreased cortical cholinergic enzyme activities. 
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Similarly, Aigner et al. (1987) used ibotenic acid to lesion the 
nbM in four monkeys. The percentage decrease in cortical CAT was as 
much as 60% when compared to control animals. 
Anatomical investigations of the connectivity of the basalis 
neurons in non-human species have suggested that these cells receive 
afferents from a variety of sources, including the amygdala, hypoth-
alamus, midbrain, and other brain stem nuclei (Jones et al., 1976; 
Aggleton et al., 1987) and that, in turn, nbM neurons project to the 
amygdala, thalamus, hypothalamus, brain stem, hippocampus, entorhinal 
cortex, and neocortex (Jones et al., 1976; Segal and Landis, 1974). 
Hence, the nbM is in a critical position to integrate information 
from a variety of sources and to directly influence the cerebral 
cortex. For example, abundant evidence suggests that cholinergic 
terminals in the hippocampus are critically important for memory 
formation (olton, 1982) in man and animals. Damasio et al. (1985) 
examined five patients with damage to the basal forebrain, and found 
behavioural disturbances featuring a prominent amnesic syndrome. 
They proposed that the memory disorder can be explained by malfunct-
ioning in the hippocampal system, secondary to damage in the basal 
forebrain structures, with which the hippocampus is strongly inter-
connected. 
In a neuropathological investigation, Whitehouse et al. (1981) 
found a 90% loss of neurons in the nbM in a patient with a familial 
form of Alzheimer's disease. In 1982, Whitehouse et al. examined the 
brains from five demented patients who had had a history typical of 
Alzheimer's disease, and who exhibited the classical pathology of 
the disease, including neurofibrillary tangles and senile plaques. 
Each of the patients with Alzheimer's disease showed a severe loss of 
nbM neurons, with an average neuron loss of over 75% when compared 
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to control subjects. Additionally, some of the remaining neurons in 
the nbM of Alzheimer's patients showed neurofibrillary degeneration. 
A key question in relation to these recent neuropathological 
findings is whether degeneration of cholinergic cells in the nbM is 
one of the most important, perhaps primary, features of Alzheimer's 
disease which may account for the clinical symptoms, or whether it 
is instead a later, secondary type of change. If it is, as Whitehouse 
et al. (1982) suggest "a critical subcortical lesion in Alzheimer's 
patients", a major loss of these neurons should be apparent in all 
established cases of the disease, and should occur in conjunction 
with the reductions in cortical cholinergic activities. 
In contrast to the Whitehouse et al. study (1982), Perry et 
al. (1982) found only a 33% neuron loss in the nbM when cell counts 
were carried out objectively, and suggest that the loss of cholinergic 
neurons may be a secondary rather than a primary change in Alzheimer's 
disease, the key pathological change being a "down-regulation" of 
transmitter-specific enzyme production in cholinergic neurons. There 
is thus some dispute in the literature regarding the precise role of 
the nbM in cholinergic loss. This is currently an active area of 
research. 
The ability to reproduce certain aspects of the neurochemical 
pathology of Alzheimer's disease in experimental animals, permits 
greater evaluation of the role of the nbM and the basal forebrain 
cholinergic pathways in the pathophysiology of the disease, than can 
be deduced from post mortem samples of human brains. Animal models 
of the dementia also allow more detailed analysis of the memory and 
cognitive deficits arising from nbM lesions than can be derived from 
Alzheimer's disease patients. Although the role of the nbM in 
behaviour and cognition has yet to be defined, as few animal studies 
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have actually been carried out in this area, psychopharmacological 
and experimental lesion studies to-date suggest that the basal forebrain 
cholinergic pathways, particularly those projecting to the hippo-
campal formation (Segal and Landis, 1974), play an important role in 
memory processes (Smith and Swash, 1978). 
In a recent study, Hepler et al. (1985) used ibotenic acid to 
destroy the nbM in albino rats, and evaluated the functional contrib-
ution of the nbM to memory in four behavioural tasks: Post-operative 
acquisition of a win-stay spatial discrimination in a T-maze; a win-
shift spatial discrimination on a radial arm maze; active avoidance 
in a shuttle box, and passive avoidance in a shuttle box. When 
compared to controls, the rats with nbM lesions had significantly 
impaired choice accuracy in the T-maze and radial maze tasks, required 
significantly more trials to reach criterion in the passive avoid-
ance task, and were impaired on retention of the active avoidance 
task. The results of these studies suggest that the nbM is involved 
in memory processes. Specifically, Hepler et al. (1985) found that 
the pattern of behavioural changes seen after lesioning the nbM was 
the same as that seen on the above tasks following experimental 
damage to the hippocampus in rats (LoConte et al., 1982; Olton, 
1982). This suggests that the cholinergic system, nbM and hippo-
campus are closely linked in a system mediating memory. 
There are, however, certain differences between the effects of 
lesions of the nbM in experimental animals, and damage to this area 
in man. For example, Wenk and Olton (1984) injected ibotenic acid 
into the nbM in rats. Seven days after injection neocortical CAT 
levels had decreased by 60%, but after three months CAT levels had 
returned to normal. Wenk and Olton (1984) propose that this may be 
the result of a compensatory increase in CAT enzyme levels within 
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surviving cortical neuronal terminals. Thus the system in animals 
shows extensive plasticity and recovery of function with time. 
Similar recovery of function has not been demonstrated in Alzheimer's 
disease patients with lesions of the nbM. 
Salamone et al. (1984) examined the results of nbM lesions in 
rats, on performance of an appetitive T-maze task involving spatial 
memory. The lesions were found to result in reduced acetylcholin-
esterase levels in the neocortex, reduced CAT levels (by approx-
imately 30%) in frontal cortex, and the disruption of rewarded 
alternation procedure. The lesioned rats showed some improvement in 
performance over 8 subsequent test days, however, and this can be 
related to the report of Wenk and Olton (1984) that reduced CAT 
activity in cortex following nbM lesions recovers over a 12 week 
period. Furthermore, the results of the study by Salamone et al. 
(1984) do not unequivocally demonstrate that nbM lesions cause a 
memory deficit on the spatial T-maze task: The lesions could have led 
to a deficit in the processing of spatial information, or to non-
specific sensory or motor biases, all of which would result in the 
observed choice inaccuracy. Similarly, a number of authors have 
demonstrated that lesions of the nbM in rats cause deficits in 
passive avoidance responding (Flicker et al., 1983; Friedman et al., 
1983; LoConte et al., 1982), and while these results are consistent 
with a hypothesised memory dysfunction caused by lesions of the nbM, 
they do not provide conclusive evidence of that hypothesis. 
In general, the evidence available so far demonstrates that 
destruction of neurons in the basal forebrain may be responsible for 
some of the cognitive disturbances occurring in those individuals 
with Alzheimer's disease, though a wider variety of test procedures 
needs to be used in order to delineate precisely the types of 
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memory function that are spared and impaired following damage to the 
nbM; to establish the reason for recovery of function in animals; and 
to eliminate the effects of confounding variables on performance of 
the tasks. 
To summarise so far: 
(l) It has been consistently demonstrated that CAT is markedly 
diminished in the cerebral cortex and hippocampal regions of patients 
with Alzheimer's disease when compared with healthy age-matched 
subjects, and with other psychiatric controls (Davis and Maloney, 
1976; Perry et al., 1978; White et al., 1977). 
(2) The number and density of neurofibrillary tangles and senile 
plaques increases in the hippocampus, cortex and amygdala of 
Alzheimer's patients compared with elderly, non-demented patients 
(White et al., 1977; Perry et al., 1978), and these authors have 
further shown that the reduced level of CAT correlates both with 
neurofibrillary change and with the number of senile plaques present 
in the brains of patients with the disease. 
(3) Finally, Whitehouse et al. (1982) found that there is extensive 
loss of neurons in the nbM of patients with Alzheimer's disease. 
They propose that the loss of neurons from this region may be res-
ponsible for the decrease in cholinergic activity observed in the 
cortex, hippocampus and amygdala, since the nbM projects to these 
areas and is thought to provide the primary cholinergic input to the 
cortex. 
1.3.5. The Cholinergic Hypothesis of Memory Loss and Scopolamine. 
The principal cognitive deficit observed in patients with 
Alzheimer's disease is a severe loss of memory, and the finding that 
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cholinergic activity is markedly reduced in the brains of Alzheimer's 
disease patients, leads to the hypothesis that cholinergic loss is 
related to the dementia, and specifically, to the memory dysfunction. 
Indeed, Perry et al. (1978) have found that the reductions in CAT 
and ACE (see P. 1 7 can be correlated to the clinical extent of the 
disease process, i.e., the lower the level of CAT, the more pronounced 
the memory loss. However, simply demonstrating that dementia-
related changes in the cholinergic system occur, does not directly 
prove that these changes might be responsible for the dementia and 
its associated memory loss. 
One method of gaining additional information about the extent 
to which changes in the cholinergic system contribute to the memory 
loss associated with age and dementia would be to pharmacologically 
impair function in this neurotransmitter system in non-demented 
subjects and compare the changes in memory ability with those occur-
ring naturally in demented subjects. If age-related changes in the 
cholinergic system contribute to the memory loss observed in 
Alzheimer's patients, pharmacological disruption of that system 
should induce similar changes in the behaviour of normal subjects. 
Cognitive deficits in demented patients typically occur in 
situations requiring recent events to be remembered, usually with-
out the benefit of extensive rehearsal or practice (Bartus et al., 
1978, 1980). The primary pharmacological data supporting an 
important cholinergic involvement in this memory deficit is that 
blockade of central muscarinic receptors by the drug scopolamine 
induces a similar deficit in recent memory in normal subjects. For 
example, Drachman et al. used a number of clinical measures to find 
that normal human subjects tested under a low dose of scopolamine 
exhibited memory (Drachman and Leavitt, 1974) and other cognitive 
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(Drachman, 1980) deficits similar to those found naturally in aged 
people with Alzheimer's disease who were tested on the same clinical 
battery. The tests which revealed the most severe deficits in both 
cases involved memory for recent events. 
In animal studies, aged monkeys tested on a number of different 
behavioural tasks have been found to suffer a very consistent and 
severe deficit on tasks requiring memory for recent sensory events 
(Bartus et al., 1978, 1980), with the greatest memory deficits 
occuring under those conditions requiring the longest retention of 
recent information. Young monkeys injected with the central cholin-
ergic receptor blocker scopolamine exhibit a deficit strikingly 
similar to that occuring naturally in the aged monkeys (Bartus and 
Johnson, 1976; Robustelli et al., 1969; Pontecorvo and Evans, 1985; 
Aigner and Mishkin, 1986), and this deficit of recent memory in 
young and aged monkeys shares many similarities with that suffered 
by demented humans. 
In general, many human studies, e.g.,Crow and Grove-White (1973), 
Sitarem, Weingartner and Gillian (1978), Richardson et al. (1984) 
etc., have reported disruptive effects on memory after the administ-
ration of scopolamine, and these studies all lend support to the 
hypothesis that a disorder of the cholinergic system might be 
related to the memory and cognitive deficits seen in Alzheimer's 
disease. 
Although animal studies which have examined the effects of 
scopolamine on memory function in both monkeys and rodents seem to 
provide additional support for this hypothesis (Evans, 1975; 
Pontecorvo and Evans, 1985; Robustelli et al., 1969; Dunnett, 1985; 
Heise et al., 1976), a number of problems associated with the studies 
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make the results (as far as scopolamine's effects on memory are 
concerned) difficult to interpret. Some of these problems will be 
discussed in Section 1.3.7., and in more detail in Chapter two. 
The human and non-human primate studies largely corroborate 
each other, and demonstrate that one of the most severe and consistent 
deficits observed with dementia occurs on tasks requiring memory for 
relatively recent events. Furthermore, of the classes of drugs 
tested on memory tasks, drugs having anticholinergic effects seem to 
produce deficits most closely (though perhaps only superficially) 
mimicking the natural, dementia-related memory impairments, which 
satisfies another logical pre-requisite for the cholinergic hypoth-
esis. When the pharmacological data are considered with the 
correlative neurochemical and neurophysiological changes discussed 
earlier, the cholinergic hypothesis does seem to be the most likely 
theory that will eventually explain some of the clinical syndrome 
associated with Alzheimer's disease, and perhaps even pinpoint the 
cause of the disease. Furthermore, there is one other area of 
research which also lends support to the cholinergic hypothesis. 
1.3.6. The Cholinergic Hypothesis of Memory Loss and Physostigmine. 
The hypothesis that the cognitive impairments of Alzheimer's 
disease patients may be a reflection of decreased cholinergic activity 
is supported by studies using anticholinergic agents, such as scopol-
amine, in normal subjects. Conversely, it should be possible to 
improve memory and cognition in both normal subjects and Alzheimer's 
disease patients by increasing cholinergic activity. 
In relation to the cholinergic neuronal system, the demonstrat-
ion of selective abnormalities on the pre-synaptic side and apparent 
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normality of receptors on the post-synaptic side (seeP. 16 ) have 
encouraged the view that some kind of 'replacement' therapy, aimed 
at increasing levels of acetylcholine in the brain, might be effect-
ive in at least partially restoring cholinergic functions. Various 
possible means of therapeutically rectifying a central cholinergic 
deficit are outlined in Table 1.3. (Pearce, 1984). Trials aimed at 
increasing acetylcholine synthesis in Alzheimer's disease via 
increased precursor (choline or lecithin) availability have not so 
far resulted in any consistent or long-lasting improvement. In 
contrast, trials of the acetylcholinesterase inhibitor, physostigmine, 
have been considerably more promising, though this drug seems to have 
a narrow effective dose range. 
For example, Davis et al. (1976) administered physostigmine 
3 mg/kg intravenously to human subjects, and found that at this dose 
the drug resulted in a decrement in all aspects of memory. In 
contrast, doses of 1 2 mg. produced a slight improvement in memory 
storage and the effect at 1 mg. was greater than for 2 mg. The 
dose of physostigmine used therefore seems to be crucial. 
Davis et al. (unpublished data) infused 0.5 mg. physostigmine 
at a constant rate over a 30 minute period, and found a significant 
improvement in long-term memory in normal (human) subjects. 
Specifically, an improvement was seen in the process of consolidation. 
In a later study, Davis et al. (1978) administered 1.0 mg. of 
physostigmine or 1.0 mg. of saline by slow intravenous infusion to 
19 normal male subjects, on two non-consecutive days, and found 
that physostigmine significantly enhanced the storage of information 
into long-term memory, as indicated by the results obtained on a 
verbal learning task. Retrieval of information from long-term 
memory was also improved, though short-term memory processes (as 
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THERAPEUTIC POSSIBILITY 
Increasing acetylcholine (ACh) 
synthesis via: 
Choline availability 
Acetyl-coenzyme A 
availability 
Decreasing ACh breakdown 
Cholinergic receptor 
stimulation 
Stimulating ACh release 
PRACTICAL APPROACH 
Oral choline or lecithin 
Choline plus piracetam 
Intravenous physostigmine 
Intramuscular arecoline 
REPORTED OUTCOME IN 
ALZHEIMER'S DISEASE 
Little or no improvement 
More encouraging results 
in aged animals and 
some Alzheimer-type 
patients 
Small but consistent 
improvements in Alzheimer's 
disease and aged animals 
Improvements in aged 
primates 
Table1.3.Theoretical therapeutic approaches to directly countering a cholinergic deficit. 
(From Pearce, 1984). 
COMMENTS 
Unclear if ACh synthesis is 
normally increased by 
supplementary choline 
Suggests metabolic 
stimulation may be 
useful adjunct in 
cholinergic therapy 
Stimulating glucose catabolism 
might increase ACh synthesis 
since the reverse is true, 
with impaired synthesis 
accompanying mild metabolic 
impairment 
Optimal dose variable; 
short-acting drugs with 
unpleasant side-effects; need 
for other anticholinesterases 
Optimal dose more consistent 
compared with physostigmine; 
current need for new muscarinic 
and nicotinic agonists 
Agents (e.g. neuropeptides) may 
directly stimulate ACh release 
mechanisms 
tested by digit span and memory scanning tasks) were not significantly 
altered by physostigmine. 
In a 1982 study, Davis and Mohs administered physostigmine 
(0.125 mg., 0.25 mg. or 0.5 mg.) or placebo intravenously to ten 
neuroleptic-free patients with Alzheimer's disease over a 30 minute 
period. All patients performed better on a recognition memory task 
while receiving physostigmine. When placebo or the dose of physo-
stigmine previously associated with an improvement in memory was 
re-administered, physostigmine again enhanced performance on a 
recognition memory task. These studies indicate that the acute 
augmentation of cholinergic activity in some patients can partially 
reverse the memory deficit of that disorder, and one specific case 
report lends credibility to this suggestion, (Peters and Levin, 1977). 
In this study (Peters and Levin, 1977), a 20 year old woman with 
a profound memory deficit secondary to an attack of herpes simplex 
encephalitis she had sustained two years earlier, was given varying 
doses of physostigmine and placebo in a double blind protocol. On 
three separate occasions following a dose of 0.8 mg. physostigmine 
given subcutaneously there was a marked enhancement in the woman's 
ability to store new information in long-term memory from short-term 
memory, as well as improvements in her retrieval from long-term 
memory. Both lower and higher doses of physostigmine did not produce 
this effect. 
Beneficial responses to physostigmine have also been reported by 
a number of other authors, e.g., Christie et al., 1981; Peters and 
Levin, 1979; Sullivan et al., 1982; Kaye et al., 1982. All of these 
studies are consistent with the neurochemical investigations of 
Alzheimer's disease and with the scopolamine data. 
Drachman (1977) gave scopolamine 1.0 mg. to normal subjects to 
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produce a memory impairment on two tasks; digit span, and free word 
recall. Half of the test subjects then received physostigmine 
(1.0 mg. or 2.0 mg. ) and half d-amphetamine, 10 mg .. [d-amphetamine 
is a catecholamine agonist that potentiates the release and interferes 
with the re-uptake of dopamine and noradrenaline: Effects on acetyl-
choline are indirect and minor (Cooper et al., 1974) though 
d-amphetamine is known to increase alertness (Estler, 1975). If 
d-amphetamine antagonised the scopolamine dementia more effectively 
than physostigmine, it would imply that disruption of memory/cognitive 
functions by scopolamine might be the result simply of behavioural 
lethargy (since scopolamine is known to produce lethargy, fatigue 
and sleepiness in humans), without clear dependence on specific 
memory-related properties of the cholinergic neuronal system), 
Physostigmine markedly improved memory and cognitive function; d-
amphetamine had no effect on memory, although alertness was improved. 
This comparison supports a specific role for cholinergic neurons in 
memory/cognitive processes. 
In addition to physostigmine, the muscarinic agonist arecoline 
has been evaluated for effects on performance in memory tasks. After 
receiving a single injection of arecoline, young adult volunteers 
exhibited significant improvements in their ability to recall 
recently learned verbal material (Sitarem, Weingartner and Gillian, 
1978). Short-term doses of arecoline have also been shown to enhance 
performance on a memory task in aged monkeys (Bartus, Dean and Beer, 
1980), and Alzheimer's patients (Christie et al., 1981). 
Hence, it is apparent that reliable improvements on tasks 
intended to measure memory can be obtained in the laboratory and 
clinic by pharmacologically manipulating the cholinergic system. The 
ability of physostigmine and arecoline to measurably improve 
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performance must be tempered, however, by the short half-life, 
narrow effective dose range and adverse side effects that are hall-
marks of both of these drugs. Peripheral side effects typical of 
muscarinic agonists such as arecoline and anticholinesterases such as 
physostigmine include increased salivation, sweating, flushing, 
slight hypertension and nausea. 
Wettstein and Spiegel (1984) attempted to reduce the adverse 
side effects by administering the post synaptic muscarinic agonist 
RS 86 (2-ethyl-8 methyl-2, 8-diazospiro-(4.5)-decane 1, 3-dione 
hydrobromide) to six patients with Alzheimer's disease, in a series 
of controlled clinical trials. Daily doses were up to 3.0 mg. 
orally for a maximum duration of six weeks. Positive clinical 
changes with regard to cognitive functions, mood and social behav-
iour were observed in four of the Alzheimer's disease patients. 
RS 86 produced typical peripheral effects, but appeared to be better 
tolerated than similar drugs such as arecoline or physostigmine. 
Nevertheless, physostigmine is still the drug most commonly used in 
order to study the congnitive improvements produced by increased 
cholinergic activity. 
The studies quoted above support the hypothesis that central 
cholinergic neurotransmission may play a role in the processing of 
recent memories, and that abnormalities of this system may underlie 
some of the symptomatic manifestations of Alzheimer's disease. 
Furthermore, the studies indicate that reversal of the cognitive 
deficit may provide an approach to the treatment of the disorder. 
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1.3.7. Animal Studies. 
Analysis of animal models of dementia not only allows for a more 
detailed characterisation of neurotransmitter related processes than 
is possible from post mortem samples of human brain tissue, but also 
allows the potential for analysis of the sequence of neurotransmitter 
changes that occurs as the dementia develops. For these reasons, 
animal models which share neuropathologic features of the human 
dementing disorders are of particular value. Consequently, there is 
a massive literature on the effects of cholinergic manipulation on 
animal memory. 
In general, it has been shown that blockade of the cholinergic 
system by scopolamine impairs learning in tasks involving discrim-
ination, passive avoidance responses, and the learning of 'fear' 
(conditioned suppression) responses (Berger and Stein, 1969; 
Chiapetta and Jarvik, 1969; Meyer, 1965; Whitehouse, 1966; Buresova 
et al., 1964). One exception occurs with avoidance tasks, where 
large doses of cholinergic blocking agents often produce 'improved' 
performance due to increased motor activity and more rapid escape 
(Renfro et al., 1972). Physostigmine may enhance learning of maze 
tasks (Whitehouse, 1966), while decreasing avoidance responses in an 
escape situation (Rech, 1968). Problems arise in the interpretation 
of these observations, however, because many factors other than memory 
and cognitive function enter into tasks of this nature. The chol-
inergic system affects many aspects of behaviour in addition to 
memory, and so many learning paradigms can be readily contaminated. 
For example, cholinergic agents influence appetitive behaviour and 
nociception, and thus interfere with reward or punishment motivation 
(Karczmar, 1976). Similarly, interference with the motor system can 
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influence the results on learning tasks without affecting the 
memory process. These studies are further complicated by differences 
in drug administration and dose. 
The animal studies underline the necessity for future human 
experimentation to use relatively standardised cognitive tasks, drug 
dose and routes of administration if comparable data are to be 
gathered. With regard to the animal work currently in progress, it 
is believed that discrimination tasks are more likely to test cognitive 
and memory functions similar to human tests, than are avoidance 
tasks (Drachman, 1977). 
1.3.8. Summary and Objective. 
There is ample evidence from both human and animal studies that 
the drug scopolamine, which blocks cholinergic (muscarinic) recept-
ors, can impair tasks of memory. Unfortunately, this same drug has 
pronounced effects upon motivation and arousal and it has proved 
difficult to dissociate these various effects. 
The present study was designed specifically to measure whether 
scopolamine produces a general depression in the performance of a 
working memory task (a task of discrimination), or whether its 
effects are most evident when the memory demands of the task are 
increased. If the latter were true, this would lend support to the 
proposal that scopolamine can have a specific effect upon memory 
processes, which supports the hypothesis that decreased cholinergic 
activity may be responsible for some of the memory and cognitive 
impairments characteristic of Alzheimer's disease. 
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1.4. Toxin Hypothesis. 
1.4.1. The Hypothesis. 
The toxin hypothesis proposes that Alzheimer's disease is 
caused by the accumulation of aluminium salts in the brain, the 
aluminium producing neuronal degeneration in regions such as the 
neocortex, the limbic system, and the basal forebrain. Since 
aluminium salts are present in a wide range of consumables including 
drinking water, certain medicines and food stuffs, the proposed link 
between aluminium and dementia is receiving considerable attention. 
Evidence of an involvement of aluminium in at least some cases of 
Alzheimer's disease has come from a variety of sources, and this 
evidence will be reviewed in the following sections. 
1.4.2. Sources of Aluminium. 
Aluminium composes approximately 80% of the earth's crust, 
making it the third most common element and the most abundant metal. 
Because aluminium has a great affinity for oxygen, it occurs only in 
the oxidised form, mainly as alumina Al 2 0 3 • Aluminium is found in 
almost 300 different minerals, especially as double silicates such 
as feldspars and micas and their weathering products, the clays. 
Aluminium is very versatile, and has many diverse uses. Hence 
aluminium production and manufacturing now ranks in third position 
behind iron and steel. 
Aluminium is found in the air, mainly as aluminosilicates 
associated with dust particles. Water may also contain large 
quantities of aluminium, and there are numerous foods and non-
prescription drugs that contain substantial amounts of added aluminium 
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(see Section 3.3. for further discussion of sources). Underwood 
(1977) recently estimated the typical daily (dietary) intake of 
aluminium to be 22 mg .. However, the innappropriate choice of foods 
and non-prescription drugs containing intentionally added aluminium 
salts can increase the daily dietary intake of aluminium 10 to 100 
fold (Lione, 1985). There is no evidence that aluminium is a 
required nutrient (Underwood, 1977), and numerous reports describe 
the neurotoxicity of this metal. While more research is done to 
determine the complex processes controlling the absorption, distrib-
ution and excretion of this metal, it would appear prudent to restrict 
the intake of aluminium in both demented and non-demented (normal) 
people. 
1.4.3. Relevant Properties of Aluminium. 
Regardless of whether or not aluminium is the cause of Alzheimer's 
disease, this metal does have several properties which means that it 
can be neurotoxic to both man and animals if it is present in the 
body in sufficiently high quantities (i.e., as might occur due to 
excretory failure): 
(1) The aluminium ion can strongly and uniquely affect the central 
nervous system because it is a powerful flocculent, and, as such, 
causes shrinkage of colloids (Bjorksten, 1982). The human brain 
contains large amounts of colloidal gels. Abnormal coagulation of 
these gels causes shrinkage, thereby severing interneuronal connect-
ions, a process similar to that occurring in dementia. 
(2) Aluminium is a strong reactant, causing cross-linkage between 
large vital molecules. Deleterious effects of cross-linkage are: 
(a) Formation of tangled molecular chains or nets which 
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progressively impede intracellular transport; 
(b) loss of elasticity of all tissues, with increased suscept-
ibility to rupture; 
(c) conversion of essential molecules into inert aggregates; 
(d) inactivity of vital molecules by creating steric hindrances, 
and; 
(e) secondary effects caused by any of the above on the accuracy 
of mitotic processes, protein and other synthesis, or 
disturbance of enzymes. 
(3) Whereas organisms have been forced to develop systems for hand-
ling other metals such as zinc, which is neurologically toxic at 
relatively low concentrations but which is needed in normal metabolism, 
aluminium has no known metabolic function. It cannot be reduced and 
can form extremely firm attachments that do not permit its removal 
by any biological means available to the organism. 
Having established that aluminium is a neurotoxic agent, I shall 
now consider a neurological syndrome in which aluminium has been 
specifically implicated - dialysis dementia. 
1.4.4. Aluminium and Dialysis Dementia. 
Aluminium has been strongly implicated in human dialysis 
dementia. This syndrome is characterised by speech difficulties, 
motor abnormalities, personality changes, seizures, loss of memory 
and progressive dementia, terminating in convulsions and death. The 
clinical features of the syndrome indicate that it is some type of 
toxic or metabolic encephalopathy. Evidence of a slow virus is 
lacking in that Alfrey et al. (1972) injected extracts of the brain of one 
demented, dialysed patient into primates. These were still experiencing no 
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adverse effect over 3.5 years later. 
There is no specific histopathology in dialysis dementia, 
although it has been shown that aluminium levels in plasma (Berlyne 
et al., 1970), bone (Parsons et al., 1971), and in particular, the 
grey matter of the brain (Alfrey et al., 1976), are considerably 
elevated in patients suffering from the dementia. Furthermore, the 
neurobehavioural syndrome described above is remarkably similar to 
that described in experimental animals which have been exposed to 
aluminium (see Section 1.4.12.). The proposed link between aluminium 
and dialysis dementia was reinforced by the reports of several 
researchers who demonstrated that the dementia is associated with 
high aluminium content in the water used to make up the dialyzate 
(Berlyne et al., 1970; Kaehny et al., 1977) and/or with intestinal 
absorption of aluminium-containing phosphate-binding gels (Clarkson 
et al., 1972; Alfrey et al., 1976). Brain grey matter aluminium 
levels were shown to vary directly with duration of dialysis by 
Alfrey et al. (1976), and a number of authors have reported that an 
elimination or reduction of dementia is observed if aluminium-rich 
dialyzate solutions are substituted with de-ionized water (Dunea et 
al., 1978; Rozas et al., 1978; Schreeder, 1979; Hagstram et al., 
1980). These studies all support a primary role of aluminium in the 
dialysis dementia syndrome. It is now generally recommended that 
de-ionized water should be used in the hemodialysis procedure. 
The reported mean brain aluminium content in patients with 
dialysis dementia ranges from 12.4 to 33.0 mg/kg in different studies 
(Alfrey, 1980; McDermott et al., 1978; Arieff et al., 1979; Mahoney 
and Arieff, 1982; Cartier et al., 1978). As would be expected with 
impaired excretory functioning, other patients on dialysis have died 
showing elevated brain aluminium, but not dementia. The aluminium 
36 
levels in such patients have not, however, been within the range of 
those with encephalopathy. While most normal brains have aluminium 
contents under 4 mg/kg the mean aluminium content for non-demented 
dialysis patients was from 3.8 to 8.5 mg/kg (Petit, 1985). Alfrey 
(1980) reported that non-demented dialysis patients may have brain 
aluminium contents of 8.5 : 3.3 mg/kg. This level of aluminium in 
the brains of cats and rabbits is sufficient to induce an encephal-
opathy and death (see Section 1.4.12.) which suggests that the human 
is more resistant to the neurotoxicologic effects of aluminium than 
some other species: Instead of requiring 3 to 6 times the aluminium 
content of normal brains to reach an encephalopathy (as in cats and 
rabbits), neurologic signs only appear in the human when the tissue 
content of aluminium reaches or exceeds 10 to 20 times that of 
normal brains. 
Elevated aluminium levels in dialysis dementia patients probably 
occur because aluminium passing from dialysis water directly into 
the bloodstream bypasses the body's two principal natural defences: 
(1) Low absorption of aluminium by the gastro-intestinal system, and 
(2) removal of aluminium by the kidneys. 
It is unclear, however, by what mechanism the aluminium should 
accumulate preferentially in the grey matter of the brain (Alfrey et 
al., 1976). Wisniewski (1985) proposes that the dialysis dementia 
syndrome may result from an aluminium overload condition brought 
about by changes in the permeability of the blood-brain barrier (BBB) 
as a result of renal failure, but this has yet to be proved. 
(Evidence relating to possible malfunctioning of the BBB is presented 
in Section 1.4.8.). 
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1.4.5. Amyotrophic Lateral Sclerosis and Parkinsonism Dementia. 
Amyotrophic Lateral Sclerosis (ALS) is a progressive disease of 
the central nervous system characterised by accumulations of fibrill-
ary material in the neuronal perikaryon. The neurofibrillary 
tangles of ALS consist of tangles of neurofilaments and not of 
paired helical filaments. ALS, along with Parkinsonism dementia (PO) 
occurs in certain isolated populations with great frequency, such as 
the Chamorros of Guam; in the Kii Peninsular of Japan; and in 
southern West New Guinea, three areas in the Western Pacific region. 
Recent studies have shown an abnormal mineral distribution in the 
soil and drinking water of these areas consisting of a virtual lack 
of calcium and magnesium coupled with high levels of aluminium and 
manganese. Examination of neurons containing neurofibrillary tangles 
from brains of cases of ALS and PD by scanning electron microscopy 
with energy-dispersive X-ray spectrometry shows greater accumulations 
of aluminium in both the cytoplasm and the nucleus in comparison to 
non-tangle-bearing neurons from control cases (Perl et al., 1982). 
Similar comparisons have revealed somewhat higher levels of calcium 
in neurons with neurofibrillary changes, but no differences in 
magnesium, silicon, manganese and iron. In addition, in the PO cases 
and in the control cases with paired helical filaments, mineralisation 
of the blood vessel walls within the globus pallidus is observed in 
which the aluminium content is considerably greater than has prev-
iously been observed in other neuropathological conditions examined 
(Wisniewski, 1985). The tentative conclusion reached from these 
results is that the pathogenesis of ALS, PD, and premature occur-
ence of paired helical filaments in neurologically normal people in 
this region may include environmental factors, especially the high 
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natural abundance of aluminium. 
1.4.6. Bulk Brain Aluminium and Peripheral Markers of Aluminium 
in Alzheimer's Disease. 
Crapper et al. (1976) and Trapp et al. (1978), using atomic 
absorption spectroscopy, described elevated aluminium levels in the 
brains of individuals with Alzheimer's disease. For example, Crapper 
et al. (1976) found that 28% of their Alzheimer's samples were 3 S.D. 
above the control mean of 4 ug/gm dry weight. These findings have 
not, however, been replicated. Markesbury et al. (1981) used instru-
mental neutron activation analysis procedures to determine the 
aluminium content of various brain regions in histologically verified 
Alzheimer's disease cases and in controls. No difference was found 
at the bulk sample level between Alzheimer's disease specimens and 
adult controls, corrected for age and sex, or when frontal, temporal 
and hippocampal specimens were compared. The observations of 
Markesbury et al. (1981) are in agreement with the findings of 
McDermott et al. (1979) who, using dry ashing and atomic absorption 
spectroscopy, detected no difference in brain aluminium concent-
rations between control and Alzheimer's disease specimens. 
The reasons for the difference in the Markesbury et al. (1981) 
data and those cited for Crapper et al. (1976) are not clear, but it 
is possible that differences existed in the occupational and 
environmental exposure to aluminium for the individuals studied, i.e.1 
many of the patients of Crapper et al. (1976) were from a region with 
a high proportion of aluminium sulphates in the metropolitan water 
supply, whereas the patients of Markesbury et al. (1981) were from 
an area of comparatively low water-aluminium content. Although 
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aluminium in the diet can come from many sources, there is general 
agreement that aluminium-treated water may make a substantial 
contribution to tissue levels of this element (Dunea et al., 1978; 
McDermott et al., 1978; and see Section 1.4.4.). 
Furthermore, while the bulk brain data of Markesbury et al. 
(1981) and McDermott et al. (1979) do not support the concept that 
aluminium has a role in Alzheimer's disease, it seems that major 
differences exist in its concentration at the submicroscopic level 
of the disease, as suggested by the X-ray spectrometry studies of 
Perl and Brody (1980). These authors described the presence of 
aluminium in the nuclei of neurofibrillary tangle-bearing neurons 
from individuals with Alzheimer's disease, but not in normal neurons 
from these patients (see next Section). Hence aluminium appears to 
be involved in the disease at the submicroscopic level, rather than 
at the bulk sample level. 
Given the failure to find clear changes in bulk brain levels of 
aluminium it is not surprising that attempts to find a measure of 
aluminium in a body compartment more accessible than the brain (for 
example, as a constituent of cerebrospinal fluid (CSF), urine, or 
circulating blood), have also met with little success. Although 
studies by Guard (1980) and Delaney (1979) suggested elevated aluminium 
levels in the CSF of Alzheimer's patients, problems of statistical 
analysis have shed doubt on Guard's data, whereas Delaney's study 
has been questioned on technical methodological grounds (Shore et al., 
19801 ) • 
Shore et al. (19801 ) compared CSF aluminium levels in five 
Alzheimer's patients with that in 16 non-demented controls, but did 
not find any significant differences between the groups. Shore et 
al. (19802 ) extended their investigation to include serum aluminium 
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levels. Again they found no significant differences between their 
15 Alzheimer subjects and controls. In a further study, Shore et al. 
(19803 ) investigated the status of circulating parathyroid hormone 
(PTH) in patients with Alzheimer's disease and age/sex matched 
elevated 
controls. In animal studies,hPTH produces increased absorption of 
aluminium from the gastro-intestinal tract and elevations of alumin-
ium in cerebral cortex. It has been proposed that PTH elevations 
may increase tissue aluminium loads in patients with Alzheimer's 
disease, but Shore et al. (19803 ) found no significant differences 
in the levels of circulating PTH between their patient and control 
groups. When PTH elevations did occur, they seemed to be related to 
the degree of renal impairment rqther than dementia. 
Shore and Wyatt (1983) studied 10 out-patients in the early to 
middle stages of Alzheimer's disease, and measured aluminium concent-
rations in the hair of the patients and age-matched controls eating 
similar diets (spouses of the 10 patients). They found that the 
Alzheimer patients had no elevations of hair aluminium concentrations 
when compared with controls (mean age 62.2 years, n=lO). 
Table 1.4. summarises the results of the studies by Shore et al. 
(19801 , 198d ), and Shore and Wyatt (1983). As yet no peripheral 
marker of aluminium in Alzheimer's disease has been found, and the 
inability of the various authors cited above to find evidence of a 
general overload of aluminium in the disease leads to the conclusion 
that othere factors must be responsible for the focal accumulations 
of aluminium in paired helical filament-containing neurons (see 
Section 1.4.9.). 
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A.D. patients 
X 
SD 
n 
Age-matched controls 
X 
SD 
n 
Hair Al in 
parts per 
million 
( mg/1) 
7.5 
4.1 
10 
6.2 
3.8 
10 
Serum Al in 
parts per 
billion 
(.ug/ 1) 
7.1 
5.9 
15 
5.9 
2.3 
8 
CSF Al in 
parts per 
billion 
(J..lg/1) 
30.7 
7.3 
5 
35.3 
10.8 
9 
A.D. = Alzheimer's Disease CSF = Cerebra spinal fluid 
Al = Aluminium 
Table 1.4. Aluminium concentrations in Alzheimer's disease patients 
and Age-Matched (Non-demented) Controls.* 
*There are no significant differences between Alzheimer's disease 
patients and controls in the aluminium content of hair, serum or spinal 
fluid. 
(From Shore and Wyatt, 1983 ). 
1.4.7. Aluminium in Neurofibrillary Tangles and Senile Plaques. 
Perl and Brody (1980) studied the elemental content of neurons 
in the hippocampus by a combination of scanning electron microscopy 
and X-ray spectrometry, in autopsy-derived brain tissue from three 
cases of Alzheimer's disease and three non-demented elderly controls. 
Of neurons with tangles examined in the cases of Alzheimer's disease, 
91.2% demonstrated a peak for aluminium within the nuclear region, 
whereas aluminium was essentially not detected in adjacent normal-
appearing neurons. In the few neurofibrillary tangle-containing 
neurons from the three elderly non-demented individuals, aluminium 
peaks were identified within the nuclear region in 88% of cells but 
were rarely encountered in the normal-appearing neurons examined in 
these cases. Silicon was also detected within the tangle-bearing 
neurons of the Alzheimer's disease cases, but was rarely seen in the 
cells of non-demented individuals. These findings indicate an assoc-
iation of focal intranuclear accumulations of aluminium with the 
presence of neurofibrillary degeneration in the hippocampal neurons 
of cases of Alzheimer's disease. A similar association is suggested 
by the data on the occasional neurofibrillary tangle-containing 
neurons of the hippocampus of elderly non-demented individuals. 
Edwardson et al. (1986) used energy-dispersive X-ray microprobe 
analysis of isolated cores and senile plaques in situ from patients 
with Alzheimer's disease. They found a co-localisation of high 
concentrations of aluminium (4 - 19%) and silicon (6 - 24%) at the 
centre of the cores. The presence of these elements as alumino-
silicates was confirmed using solid-state aluminium nuclear magnetic 
resonance. These findings provide a link with the other major neuro-
pathological feature of Alzheimer's disease, the neurofibrillary 
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tangle-bearing neurons, where high intracellular levels of aluminium 
and silicon have also been reported (see above). 
Several factors point to the possibility that the deposition of 
alumino-silicates may be an essential stage in plaque formation. 
Their localisationat the centre of the core suggests an early involve-
ment in plaque formation since secondary deposits would be more 
likely to be peripheral or homogenous throughout the core. Also, if 
the presence of aluminium and silicon simply reflects non-specific 
binding by pre-existing core material it seemslikely that other elem-
ents such as calcium, iron, magnesium and potassium would be present 
to the same extent, but this is not the case (Edwardson et al., 1986; 
Candy et al., 1984, 1985, 1986). Even if the deposition of alumino-
silicates is secondary, the space occupying effect of these bulky 
inorganic deposits makesit highly probable that they would contribute 
to the disruption of adjacent neuronal and glial processes. 
The mechanism of alumino-silicate formation and deposition in 
the plaque core is at present unknown - this is also true of the 
deposition of aluminium and silicon in tangle-bearing neurons. While 
there is a general view that the involvement of aluminium in Alzheimer's 
disease is non-specific or may reflect an increased uptake by degen-
erating neurons, the studies of Perl and Brody (1980) and Edwardson 
et al. (1986) show that, irrespective of total brain load, plaque 
and tangle related aluminium is massively increased in Alzheimer's 
disease since these lesions are much rarer in normal subjects. 
Further research is needed to elucidate the mechanism whereby alumin-
ium accumulates in tangles and plaques (and most importantly, whether 
this is a primary cause or secondary consequence of the disease) 
although at present the most favoured explanation involves a possible 
malfunction of the blood-brain barrier. 
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1.4.8. Blood-Brain Barrier. 
In order to be absorbed by neurons, aluminium must first 
penetrate the blood-brain barrier (BBB) (Bardbury, 1984). Several 
lines of evidence suggest the competence of this barrier varies 
widely among mammalian species (Crapper McLachlan et al., 1985). 
Compared to cats or rabbits, rodents and primates are relatively 
resistant to the encephalopathic effects of either intravenous or 
intracranial injections of aluminium (King et al., 1975). It has 
been hypothesised that an abnormally functioning BBB of unknown 
cause allows endogenous, behaviourally active substances to gain 
access to the brain (Kastin et al., 1981; DeBoni et al., 1980). 
Banks and Kastin (1983) investigated the possible role of aluminium 
in the aetiology of this postulated BBB dysfunction. Their study 
showed that aluminium affects the permeability of the BBB of rats to 
small peptides. Intraperitoneal injections of aluminium chloride 
increased the permeability of the BBB to iodinated N-Tyr-delta-sleep-
inducing peptide and B-endorphin by 60 - 70%. Thus, aluminium can 
affect the BBB in ways that might be involved in dementia. I-N-Tyr-
DSIP and I-S-endorphin are representative of the small behaviourally 
active peptides that are present in both the brain and the periphery. 
An increase in the permeability of the BBB to these or other substances 
could lead to changes in brain biochemistry and behaviour that might 
ultimately result in dementia, e.g.,Alzheimer's disease or dialysis 
dementia, or other expressions of central nervous system (CNS) 
disorder. 
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1.4.9. Factors which may be Responsible for the Focal Accumulations 
of Aluminium in Paired Helical Filament-Containing Neurons. 
Aluminium could accumulate preferentially in paired helical 
filament (PHF) -containing neurons as a result of an increased vuln-
erability of neuronal DNA to aluminium (Crapper et al., 1980; Liss 
et al., 1976; Shore et al., 19802 ), which in turn could result from 
genetic factors, viral or virus-like infection, or causes unknown: 
Down's syndrome (trisomy 21) and viral illnesses such as subacute 
sclerosing panencephalitis and postencephalitic Parkinsonism are 
associated with PHF-bearing neurons in the brain. Or it may be that 
certain neurons of Alzheimer's disease patients' brains are unable 
to detoxify the aluminium that is normally present in all body tissues. 
The resulting accumulations of aluminium on nuclear chromatin could 
have neurotoxic effects. 
Another possibility is that aluminium accumulations may be a 
secondary, relatively non-specific 'marker' of neurons that are 
degenerating, rather than an etiological factor. But not all types 
of neuronal destruction lead to aluminium accumulation in the brain, 
as Creutzfe1dt-Jakob disease patients have normal brain aluminium 
concentrations (Traub et al., 1981). Creutzfeldt-Jakob disease brains 
do not typically have neurofibrillary degeneration with PHFs, however, 
and aluminium accumulations are generally associated with PHF-bearing 
neurons in degenerative brain diseases (Perl and Brody, 1980; Perl 
et al., 1982). It is still possible that the neurofibrillary degen-
erative changes in the neurons of patients with PHF-related diseases 
allow aluminium to enter the nuclei of such neurons, without result-
ing in neurotoxic effects. 
At present it is possible only to put forward tentative suggest-
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-ions as to why aluminium should accumulate in tangle-bearing neurons 
in Alzheimer's disease. The issue of whether aluminium is a cause 
of the disease or merely a consequence, will be taken up in Chapter 
three. Certainly, if aluminium was a primary cause of Alzheimer's 
disease one might expect to find elevations of this metal in serum 
or cerebrospinal fluid, if not in bulk brain samples, but as discussed 
in Section 1.4.6., this is not the case. 
1.4.10. Comparison of the Level and Distribution of Aluminium in 
Alzheimer's Disease and in Other Disease States. 
As noted in Section 1.4.6., Crapper et al. (1976) found elev-
ated bulk brain levels of aluminium in cases of Alzheimer's disease. 
Even though their data has not been replicated, a close examination 
of the figures indicates that the overall means for aluminium are 
still considerably lower than those found in dialysis dementia: 
All overall means are less than 5 mg/kg and the majority have ranges 
within those found in non-demented dialysis patients. Although the 
levels reported by Crapper et al. (1976) are clearly elevated above 
those for controls (and are within the encephalopathic range for cats 
and rabbits), they do not appear to be within the general encephal-
opathic range for humans. However, this observation must be made 
with caution due to a number of factors: 
(1) The distribution reported is patchy, and elevated levels in 
certain areas may reach toxic levels; 
(2) our knowledge of the encephalopathic levels for aluminium in 
humans is gained from diseased populations, and may not represent 
true toxicologic data; 
(3) aluminium may exert its effects through different neurobiologic 
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mechanisms in the two diseases. 
Some support may be found for the third possibility in the 
finding that the aluminium in the neurons of dialysis patients is 
located in the cytoplasm of cells, rather than being associated with 
the nucleus as is seen in Alzheimer's disease (Crapper and DeBoni, 
1978). Although the aluminium concentration in dialysis dementia 
may be several times greater than that observed in Alzheimer's 
disease, there is only one report in the literature of neurofibrill-
ary tangles and plaques in dialysis dementia brains (Brun and Dictor, 
1981). In this study, tangles and plaques were found in three of 
five patients with dialysis dementia, but they were few in number, 
and the distribution differed markedly from that seen in Alzheimer's 
disease, being particularly sparse in the hippocampus and amygdala. 
One would expect that if aluminium plays a toxic role at the cell-
ular level in both dialysis dementia and Alzheimer's disease, 
there would be more neurobiologic similarities between the two 
diseases. 
A further difference between Alzheimer's disease and dialysis 
dementia is that high serum levels of aluminium are found in the 
latter (Alfrey et al., 1976; Berlyne et al., 1970), but not in the 
former (see Section 1.4.6.). The one major similarity between the 
two appears to be in the clinical syndrome of motor impairments, 
ataxia, and memory and learning impairments, which are apparent in 
both disorders. 
Elevations of brain aluminium concentrations are present in a 
variety of human disease states associated with impairments of the 
the blood-brain barrier (e.g.1 metastatic carcinoma) which, like 
dialysis dementia, are not generally associated with Alzheimer-like 
degenerative changes in the brain (Arieff et al., 1979). On the 
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other hand, neurons containing neurofibrillary tangles are common in 
patients with the ALS-PD complex of Guam (see Section 1.4.5.) and 
are present in small numbers in non-demented elderly men and women. 
In such cases, as in Alzheimer's disease, aluminium is found in the 
nuclei of the tangle-bearing neurons (Perl and Brody, 1980; Perl et 
al., 1980), although the tangles seen in the ALS-PD complex do not 
consist of paired helical filaments. 
Comparisons of aluminium in Alzheimer's disease and other disease 
states reveal a number of differences in both the level and distrib-
ution of this metal. However, sufficient similarities exist between 
the various disorders to merit further investigation into the toxin 
hypothesis of Alzheimer's disease. Furthermore, the results available 
to-date from animal studies also support a possible toxic role of 
aluminium in the disease, as will be seen in Section 1.4.12 .• 
1.4.11. Other Metals in Alzheimer's Disease. 
Besides aluminium, other metal ions have been studied for a 
pathogenic role in Alzheimer's disease. Crapper et al. (1978) 
examined cerebral tissue for concentrations of lead, iron, manganese, 
copper, zinc and cadmium. They found no abnormality in metal content 
in either whole tissue or nuclei of Alzheimer brains. A deleterious 
function for any of these heavy metal ions is accordingly considered 
unlikely. 
1.4.12. Animal Studies. 
Elevated levels of aluminium in the brains of adult rabbits and 
cats cause a syndrome characterised by behavioural, anatomic, 
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electrophysiological, and neurochemical alterations. Approximately 
seven to ten days following brain aluminium infusion, behavioural 
changes can be observed. Learning and memory impairments have been 
noted in a variety of testing situations by different investigators. 
Crapper and Dalton (1973 1 + 2 ) found short-term memory deficits in 
cats on a delayed response procedure and acquisition deficits on a 
conditioned (one-way) active avoidance task. In adult rabbits, 
Petit et al. (1980) found both learning and retention deficits on a 
one-way active avoidance task following aluminium infusion, while 
Yokel (1983) found a classical-conditioning learning deficit follow-
ing systematic aluminium administration. 
In addition to the learning and memory deficits, subtle deficits 
in motor coordination are detectable within a week of infusion. 
These symptoms steadily increase as the animals enter a progressive 
encephalopathy. There is a deterioration in motor capacities, with 
the animals becoming rapidly incapacitated. In the final stages the 
animals become apathetic and frequently show focal or generalised 
seizures prior to death (Crapper and Dalton, 1973 1 ; Petit et al., 
1980; Klatzo et al., 1965; Crapper, 1976). Alterations are also 
noted in neural spontaneous firing rates, evoked potentials, and the 
EEG prior to and during the encephalopathic stage (Petit, 1983). 
The neurobehavioural syndrome is remarkably similar to that seen in 
dialysis dementia (see Section 1.4.4.). 
When the brains of these animals are examined histologically, 
neurofibrillary tangles are observed. These appear in cat and 
rabbit brains with aluminium concentrations of 4- 8 ug Al/g dry 
weight or greater (Crapper and Tomko, 1975). Neurofibrillary degen-
eration is not observed with whole cerebral cortical tissue concent-
rations of below 4 ~g Al/g dry weight (Crapper and DeBoni, 1980). 
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It is important to note, however, that the aluminium-induced tangles 
are different from those found in Alzheimer's disease: Both tangles 
are composed of accumulations of 10 nm. neurofilaments, but the 
filaments in the Alzheimer tangle are twisted in a double helix 
while those in the aluminium tangle are not. Cultured cortical 
neurons taken from aborted human foetuses and exposed to aluminium 
salts develop neurofibrillary tangles made up of 10 nm. filaments 
indistinguishable from those found in aluminium treated animals, and 
not paired helical filaments as found in Alzheimer's disease (Crapper 
et al., 1978). These observations suggest that aluminium salts 
induce neurofibrillary changes with a common structure in human and 
animal nerve cells. Further differences between aluminium-induced 
neurofibrillary changes and PHF are found in the topography. In 
aluminium treated animals, neurofibrillary changes occur extensively 
throughout the spinal cord and in specific regions of the hippocampus 
(Wisniewski et al., 1965; Klatzo et al., 1965). In Alzheimer's 
disease, neurofibrillary changes are not found in the spinal cord 
(Hirano and Zimmerman, 1962). 
Also, neurofibrillary changes in Alzheimer's disease are assoc-
iated with the presence of senile plaques. Senile plaques are not 
found in aluminium treated animals. In this respect the aluminium 
induced encephalopathy is similar to the ALS-PD complex of Guam, in 
which many neurons in the cortex show neurofibrillary tangles without 
the presence of senile plaques. Finally, there has been some evid-
ence presented that aluminium induced neurofibrillary degeneration 
in animals can disappear and that affected cells can recover (Troncoso 
et al., 1982; Wisniewski, Sturman and Shek, 1980), though the mechan-
ism of this recovery is not known. There is no evidence, however, 
of recovery from neurofibrillary degeneration in patients suffering 
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from Alzheimer's disease. In spite of these differences there are 
sufficient similarities to warrant the use of aluminium induced 
neurofibrillary changes as a model for the changes found in Alzheimer's 
disease. For example, and perhaps most importantly, both Alzheimer 
and aluminium tangles are space occupying lesions which reduce the 
life supporting machinery of nerve cells. 
The effects of aluminium exposure are developmentally dependent 
in animals, with younger animals being more resistant to the behav-
ioural and encephalopathic effects (Wisniewski et al., 1980; Petit 
et al., 1985). Although neurofibrillary tangles are seen in the 
rabbit following perinatal infusions of approximately the equivalent 
(based on brain weight) adult dose of aluminium, behavioural and 
encephalopathic changes are not observed. At approximately twice 
the adult dosage, reductions in dendritic development are seen (dend-
ritic development was not examined at lower doses) but no encephal-
opathic signs or alterations in learning and memory are observed. 
Overt neurologic signs are observed only following three times the 
relative adult dose, and 26.7% of these animals still showed no 
encephalopathic signs 17 days post-infusion (Petit et al., 1985). 
These findings suggest that the infant rabbit is a more appropriate 
animal model of aluminium neurotoxicity than the adult, the lack of 
encephalopathy making behavioural testing considerably easier. 
Another important finding from the experimental animal research 
is the large species differences in reaction to aluminium. The 
characteristic neurobehavioural response to aluminium described above 
is readily produced in cats and rabbits. The rhesus macaque monkey 
also develops tangles, but only after a prolonged period, i.e., 380 
days or more (DeBoni et al., 1976). However, rats and mice develop 
neither neurofibrillary tangles nor an encephalopathy at 10 times the 
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dose effective in cats and rabbits (King et al., 1975). The rat 
does, however, show behavioural alterations with elevated aluminium 
levels. For example, Bowdler et al. (1979) found that oral admin-
istration of high doses of aluminium to rats resulted in increased 
activity, and increased sensitivity to flicker. Thorne et al. (in 
press) report an inverse relationship between brain aluminium and 
open-field activity (i.e.,as aluminium levels increase, activity 
decreases) and a correlation between high aluminium levels and poor 
performance on tasks of single-trial passive avoidance and visual 
discrimination with reversal. However, not all researchers have 
found such changes (King et al., 1975). It remains a possibility, 
therefore, that different species, like individuals at different 
developmental ages, may have either different neurobiologic responses 
to aluminium, or different thresholds for this response. 
Before turning to a consideration of possible methods of therapy 
based on the toxin hypothesis, it should be pointed out that there 
are two principal problems with the animal studies cited above: 
(1) The neurotoxic effects of aluminium typically limit the duration 
of study and necessitate that aluminium injected animals be tested 
within one to two weeks after injection. They also complicate the 
interpretation of the cause of the learning deficits observed in 
aluminium treated animals, because the deficits could arise not only 
from neurofibrillary changes, but also from seizures and/or motor 
impairments. 
(2) To remedy these limitations, a new chronic rabbit model for 
aluminium induced neurofibrillary degeneration was developed by 
Wisniewski et al. (1980) which was based on the infant rabbit (see 
above). However, it has already been noted that there are species 
differences in response to aluminium (see above and P. 37 :Section 
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1.4.4.), with cats and rabbits showing rapid neurobehavioural 
changes following aluminium administration, and rats and mice, very 
little change. Since it has been demonstrated that humans are also 
naturally resistant to the effects of aluminium (see Section 1.4.4.), 
this implies that the cat or rabbit is not necessarily the best 
model of the human dementing syndrome. Rather, it could be more 
worthwhile to develop the rat or mouse model. This point will be 
taken up again in Section 1.4.14., and in Chapter three. 
1.4.13. Therapy. 
Several research groups have been studying possible ways to 
prevent aluminium from gaining access to the DNA in neuronal nuclei, 
in the hope of preventing neurotoxicity and clinical deterioration. 
There are a number of possible approaches to this problem. One can 
attempt to eliminate all sources of aluminium intake, but this is 
not really possible since aluminium is present in all foods, in air, 
water, dust, etc .• Another approach is to minimise the absorption 
of the aluminium which is ingested. A third possibility is to 
attempt to facilitate the excretion of aluminium, for example, by 
chelation with drugs like desferroxamine. 
Desferroxamine (DFO) is a trivalent metal chelating agent that 
binds iron with high affinity and specificity. DFO has been widely 
employed to treat patients suffering from iron overload, and has 
been used to remove aluminium from patients with renal failure who 
were stabilised on standard hemodialysis (Ackrill et al., 1980). 
More recently, DFO has been employed in an attempt to remove aluminium 
from the brains of patients suffering from Alzheimer's disease 
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(McLachlan- report in progress). 
A recent preliminary report by King et al. (1985) stated that a 
single subcutaneous administration of DFO (100 mg/kg) two hours 
after intracisternal injection of aluminium chloride (1 mg. intra-
cranially) in rabbits, followed by 33 mg/kg of DFO at three-day 
intervals, did not generally prevent the aluminium induced encephal-
opathy in three of four animals. These workers concluded that 
"there is no evidence that systemic administration of desferroxamine 
can remove aluminium from the central nervous system". This conclusion 
is in contrast to the previously published observations on dialysis 
dementia ln which DFO treatment resulted in reversal of the neurologic 
symptoms (Ackrill et al., 1980). 
The observations of Crapper McLachlan et al. (1985) employing 
DFO treatment in both patients with Alzheimer's disease and aluminium 
overload indicate effective aluminium removal. In aged patients with 
Alzheimer's disease under long-term DFO treatment and who died of 
unrelated illness, neocortical brain analysis revealed near normal 
concentrations of aluminium. In aluminium overload conditions in the 
presence of normal renal function, DFO treatment (7 mg/kg bi-daily) 
resulted in an initial 50-fold increase in excretion of aluminium 
(Crapper McLachlan et al., 1985). During prolonged aluminium treat-
ment, excretion was approximately three times the pretreatment level. 
These observations support continued clinical trials of DFO under 
controlled conditions for aluminium-associated diseases. 
A related method of aluminium removal to the above is to admin-
ister an anion which complexes aluminium in the body, in the hope of 
lessening the ability of aluminium to complex with nuclear chromatin 
in the brain. Such an anion might also facilitate the excretion of 
aluminium from the body. 
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It has recently been reported that aluminium in man binds 
fluorine in the gastro-intestinal tract, and prevents the absorption 
of excessive dietary fluorine (Spencer et al., 1981). Shore et al. 
(1985) considered the possibility that the converse might be true -
that complexation of fluorine with aluminium might diminish alumin-
ium toxicity. Ondreicka et al. (1971) had previously studied 
nutritional aspects of aluminium and fluorine and reported that 
feeding rats large doses of aluminium caused elevated aluminium 
concentrations in a variety of tissues, including the brain. Feeding 
fluorine along with aluminium prevented these increased concentrations, 
and increased aluminium excretion. On the basis of this report 
(Ondreicka et al., 1971), Shore et al. (1985) conducted a study to 
determine whether increasing fluorine concentrations in man might 
provide a way to bind aluminium, reduce its cationic charge, and 
facilitate its excretion: In a series of rabbits, half were given 
fluorine in their water for several days, before all rabbits 
received intrathecal aluminium injections. Fluorine pretreatment 
was found to result in lower brain aluminium concentrations on 
sacrifice, indicating that fluorine may prevent aluminium induced 
neurotoxicity. Since this implies that fluorine administration may 
be a possible form of treatment for Alzheimer's disease, dialysis 
dementia, aluminium overload conditions, etc., further research in 
this area is certainly warranted. 
Some may feel that clinical studies of anti-aluminium drugs are 
premature (Cole and Branconnier, 1978), as the association between 
aluminium and Alzheimer's disease is far from clear and consistent. 
However, it might be possible to demonstrate therapeutic effects of 
anti-aluminium drugs before the basic scientific questions are 
answered. This is not very different from the searches for drug 
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treatments for depression or schizophrenia, searches which have met 
with remarkable success. 
Furthermore, if it can be demonstrated that therapy with DFO or 
fluorine is capable of both reducing aluminium levels and alleviating 
the clinical symptoms of Alzheimer's disease, this will provide very 
strong evidence in favour of a causal role of aluminium in this 
disease, and might also provide valuable information on the mechanism 
whereby aluminium accumulates on nuclear chromatin. 
1.4.14. Summary and Objective. 
Evidence for an involvement of aluminium in Alzheimer's disease 
has arisen from a variety of sources: Elevated concentrations of 
aluminium have been found in some brain regions of such patients and 
there is evidence that aluminium is present in a high percentage of 
neurons containing neurofibrillary tangles, while it seems to be 
absent in adjacent neurons that appear normal (Crapper and DeBoni, 
1980; Crapper, 1976). Of particular interest is the recent finding 
that aluminium is also present in the core of senile plaques, most 
probably compounded as an alumino-silicate (Candy et al., 1986; 
Edwardson et al., 1986). Thus aluminium appears to be closely linked 
to those diagnostic neuropathological features of Alzheimer's 
disease. Aluminium has also been implicated as a toxic factor in 
dialysis encephalopathy, an irreversible dementia seen in some people 
who have undergone repeated kidney dialysis with aluminium-rich 
solutions (Alfrey et al., 1976). Lastly, it has been shown that 
there are prominent accumulations of aluminium in the cytoplasm of 
neurofibrillary tangle-bearing neurons in the hippocampus in a form 
of Parkinsonism associated with severe dementia seen in certain 
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native communities on the island of Guam in the Western Pacific (Perl 
et al., 1982). 
These clinical data are supported by studies of the experimental 
encephalopathy induced by the intracranial injection of soluble 
aluminium into animals such as cats and rabbits (Crapper and DeBoni, 
1980; Crapper, 1976). These animals may exhibit memory impairments, 
as evidenced by impaired acquisition and retention of avoidance 
responses and impaired learning of spatial tasks. Subsequently the 
animals become slower in their movements and develop ataxia. Finally 
general convulsions are observed, the animals usually dying within 
10 - 28 days of the injection of aluminium salts. Post mortem 
analyses have shown that the animals' brains contain a significant 
percentage of neurons which have undergone neurofibrillary degener-
ation. These neurons, which contain dense parallel arrays of 10 nm. 
single filaments, bear general similarities to those observed in 
Alzheimer's disease. 
Attempts to treat aluminium overload conditions and Alzheimer's 
disease by the administration of desferroxamine or fluorine (in 
order to facilitate the excretion of aluminium and prevent aluminium 
from accumulating in the brain) have yielded encouraging results 
(Shore et al., 1985; Crapper McLachlan et al., 1985), thus providing 
further support for an involvement of aluminium in the disease. 
Finally, there is no evidence of a similar involvement of any other 
metal in Alzheimer's disease (Crapper et al., 1978). 
Although Alzheimer's disease can be linked with the occurrence 
of aluminium in the brain, the critical question is whether the 
presence of aluminium is a secondary consequence of the disease or 
whether aluminium itself is responsible for the disease. The apparent 
lack of elevated aluminium concentrations in bulk brain analysis, 
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serum or cerebrospinal fluid of Alzheimer disease patients (Markesbury 
et al., 1981; Shore et al., 1980 1 , 1980 2 ) suggests that aluminium 
alone is not a 'cause' of Alzheimer's disease. Aluminium may be just 
a 'marker' of paired helical filament-bearing neurons, or Alzheimer 
disease patients may be 'vulnerable' to aluminium neurotoxicity on 
the basis of some other neuronal dysfunction (e.g., malfunction of 
the blood-brain barrier), allowing aluminium to enter neuronal nuclei. 
The rate of deposition in tangles and plaques would, in addition, be 
determined by the extent of environmental exposure to aluminium. 
The only direct way of investigating the precise role of 
aluminium in Alzheimer's disease is to determine whether conditions 
which lead to increased aluminium uptake produce dementia. Chapter 
three will examine this question experimentally by assessing the 
correlation between aluminium uptake and cognitive performance in 
laboratory animals. The behavioural tasks will concentrate on meas-
ures of recent memory as this is one of the first cognitive disorders 
to appear in Alzheimer's disease. 
In order to assist aluminium uptake the animals will be given a 
diet which is high in aluminium salts, but lacking in calcium and 
magnesium. This novel manipulation follows from recent epidemiolog-
ical evidence that a deficiency of these metals potentiates the up-
take of aluminium (Perl et al., 1982), an innovation which provides 
the opportunity to challenge the toxin hypothesis and produce an 
animal model with direct value for the assessment of possible prevent-
ative treatments and therapies. 
Rats will be used as the subjects of study since the available 
evidence suggests that these animals have a natural resistance to 
aluminium neurotoxicity in the same way as man (King et al., 1975; 
Petit, 1985), thus making them a more appropriate species on which 
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to develop an animal model of the toxin hypothesis of Alzheimer's 
disease than the cat or rabbit which have typically been used. 
59 
1.5. Overall Objectives. 
The overall objectives of this study are: 
(1) To examine two hypotheses of the cause of Alzheimer's disease; 
the cholinergic hypothesis, and the toxin hypothesis. 
(2) Specifically, (since amnesia is one of the most severe symptoms 
of Alzheimer's disease) to assess the effect on memory of cholinergic 
manipulations (Chapter two) and the ingestion of a diet with a high 
aluminium content (Chapter three). 
(3) To achieve (1) and (2) by developing an animal model of the 
human amnesic syndrome using the rat as the species of study. 
(4) To base the experiments of Chapters two and three on a nonspatial 
task of working memory, (delayed) nonmatching-to-sample, which is 
comparable to tasks used to assess memory impairments in man, but 
which has not been used before to study learning and memory in 
rodents. 
60 
CHAPTER TWO. CHOLINERGIC STUDY. 
2.1.1. Introduction. 
There is substantial evidence from human studies that drugs 
such as scopolamine, which disrupt cholinergic transmission, can 
produce impairments in memory (Crow and Grove-White, 1973; Drachman 
and Leavitt, 1974; Sitarem et al., 1978) (seeP. 25 ). Similar 
findings have been reported in studies of experimental animals. 
Unfortunately scopolamine, a muscarinic blocker, appears to have 
multiple actions and it is uncertain whether the observed deficits 
in animals reflect a primary dysfunction in memory or whether they 
are a secondary consequence of changes in attention, perception, or 
motivation. 
For example, Evans (1975) found that scopolamine impaired 
discrimination performance by monkeys in a way that mimicked alter-
ations in stimulus luminance. Evans (1975) argued that a drug 
induced impairment of visual acuity, resulting in reduced stimulus 
sensitivity, was responsible for the marked decrement in choice 
accuracy on the task, independent of any effect scopolamine might 
have on memory processes. Warburton and Brown (1971) had previously 
used signal detection theory to reveal dose dependent decreases in 
stimulus sensitivity (d') with systemic injections of low doses of 
scopolamine (0.062 - 0.25 mg/kg) on a discrimination task with rats. 
They, as in the later Evans (1975) study, argued that scopolamine's 
effects were on sensory or attentional processes rather than on 
memory functioning. 
One approach to the problem of defining the precise effects of 
scopolamine (i.e.1 whether its effects are on memory or on sensory or 
attentional processes) has been to assess whether scopolamine pro-
duces a depression in performance when the mnemonic demands of a task 
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are reduced to a minimum, or whether its effects are only pronounced 
when the mnemonic demands are high. This distinction has been 
examined by looking at the effects of scopolamine upon the slope of 
forgetting curves. Such studies, which have typically used tests of 
spatial working memory in order to generate forgetting curves have, 
however, produced inconsistent results. For example, Heise et al. 
(1976) trained rats on a spatial alternation task. The rats were 
then pretreated with scopolamine, and the interval between trials 
was varied. Drug treatment did not, however, interact with delay 
interval, and so it was concluded that pretreatment with scopolamine 
did not affect memory storage. 
In contrast, Bartus and Johnson (1976) demonstrated a highly 
significant interaction between scopolamine pretreatment and delay 
interval using an automated, 9-choice delayed response task. They 
found that with a low scopolamine dose (10- 15pg/kg), performance 
on the task was unimpaired with zero delays, but fell to approximately 
40 - 70% at 10 second delays when compared to saline controls. 
Doses higher than 20- 30pg/kg impaired accuracy at all intervals, 
including zero delay conditions. Bartus and Johnson (1976) argued 
that " ••• the disruption of short-term memory by interference with 
central cholinergic mechanisms essential to the process remains the 
most parsimonious interpretation of these observations". Yet other 
studies (Robustelli et al., 1969; Dunnett, 1985) are in agreement 
with the results of the Heise et al. (1976) study, failing to find an 
interaction between delay interval and pretreatment with scopolamine 
indicative of a true memory impairment. 
In view of these inconsistent results, the present study re-
examined the effect of scopolamine on memory, and more specifically, 
on the slope of a forgetting curve, by using a non-spatial test of 
62 
working memory, delayed nonmatching-to-sample. This test of object 
recognition has recently been shown to be sensitive to scopolamine 
in the monkey: Aigner and Mishkin (1986) examined the effects of 
scopolamine upon delayed nonmatching-to-sample, using a sample set 
of 1200 junk objects. They had no difficulty in training monkeys to 
non-match after seeing lists of up to 20 objects and sample-choice 
intervals of 5 minutes. Scopolamine (1.0- 32.0yg/kg) caused a dose 
dependant impairment of performance on the task, though in the absence 
of data concerning different delay intervals or list lengths, no 
specific conclusions about cholinergic involvement in recent memory 
could be drawn. Nevertheless, the delayed nonmatching-to-sample 
procedure with trial-unique stimuli is promising. In terms of com-
parability with the human data it would seem to be a particularly 
appropriate task to use with animals, since it is known that visual 
recognition abilities are considerably reduced in patients suffering 
from Alzheimer's disease, and these deficits are still apparent when 
the subject is tested using a delayed nonmatching-to-sample procedure 
which is deliberately modelled on those used with primates (Albert 
and Moss, 1984). Furthermore, and perhaps most importantly, 
nonmatching (or matching)-to-sample tasks can be non-spatial, and 
therefore are most similar to the tasks given to humans which are 
typically non-spatial (Drachman and Leavitt, 1974; Sitarem et al., 
1978). 
Just as drugs which disrupt cholinergic transmission can impair 
cognitive performance, so drugs such as physostigmine which increase 
available acetylcholine can improve performance on some tests of 
learning and memory. For example, Davis et al. (1978) found that 
physostigmine enhanced both the storage and retrieval of information 
in long-term memory in humans, and Dunnett (1985) demonstrated that 
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physostigmine can induce a mild but significant enhancement of 
performance in rats trained on a delayed matching-to-position task. 
In view of recent evidence that physostigmine can improve 
delayed nonmatching-to-sample performance in the monkey (Aigner and 
Mishkin, 1986), the effects of this drug were tested upon an anal-
ogous task for rats. 
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Experiment One. 
2.1.2. Introduction. 
The first experiment examined whether scopolamine impaired 
performance on a test of object recognition, delayed nonmatching-to-
sample. In this task the rat is rewarded for selecting between two 
goal boxes, one of which differs from the start box (Figure 2.1. ). 
This task taxes working memory as both the start and goal boxes are 
changed after every trial. 
The results of a pilot study suggested that the best dose range 
in which to look for a memory impairment (specifically, an interaction 
between drug and task difficulty) and to minimise the peripheral 
effects of the drug, should be not more than 0.05 mg/kg scopolamine 
hydrochloride, and this was taken into account in the doses used in 
the present study. 
Experiment One also included concurrent sessions in which the 
rats received either scopolamine methylbromide, or the acetylcholin-
esterase inhibitor, physostigmine. Methylscopolamine has the same 
peripheral actions as scopolamine, but it does not cross the blood-
brain barrier and hence does not mimic its central actions. The dose 
of 0.03 mg/kg scopolamine methylbromide was selected again on the 
basis of the pilot experiment, which indicated that this is the 
highest dose which can be used and not affect performance at the 
shortest retention interval on the task. The dose of physostigmine 
was determined from other studies which have reported that this drug 
can improve performance (Aigner and Mishkin, 1986; Dunnett, 1985; 
Hagan and Morris, 1987). 
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Figure 2,1, 
Diagrammatic representation of the nonmatching-to-sample procedure 
in which the animal was rewarded for choosing the novel goal box. 
Arrows show the direction of correct choices. 
2.1.3. Method. 
Subjects. 
The subjects were 8 male pigmented rats of the DA strain, 
supplied by Bantin and Kingman, Hull. The rats were housed individ-
ually and were maintained on approximately 18 g. of laboratory chow 
each day. The chow was always mixed with water to form a gruel -
this minimised the effects of the drugs upon the animals' daily 
consumption of food. Water was freely available in the home cage. 
The rats were aged about 14 weeks at the start of the experiment. 
Apparatus. 
The animals were tested in an aluminium Y-maze (Figure 2.2. ). 
Each maze arm was 12.7 em. wide, 20 em. high, and covered with a wire 
grid. Fifty pairs of hardboard boxes served as both start boxes and 
goal boxes. These boxes could be fitted into the end of each arm of 
the maze, forming an arm length of 26 em .. The boxes in each 
pair were made as similar as possible, but each pair was distinctive. 
This was achieved by painting the walls and floors a variety of 
colours and patterns, and lining the floors with materials such as 
sandpaper, wooden strips, metal, perspex and cloth. In addition, 
each pair of boxes contained an identical object, such as a plastic 
cup, a metal bracket, or a wooden block, although no two pairs cont-
ained the same object. The boxes were 11.5 em. wide, 9 em. long and 
either 16 or 19 em. high. The floors protruded an additional 9 em. 
from the box, so that the floor of each box began 8 em. from the 
centre of the Y-maze. An aluminium guillotine door was set in the 
centre of the maze, blocking the three arms. Metal tubes, which 
dispensed the reward pellets (45 mg., Campden Instruments Ltd.), ran 
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Schematic representation of Y-maze, indicating maze dimensions. 
to the back wall of each start box which had been cut away to allow 
the animals access to food. The rats were allowed constant access 
to dilute orange juice from fluid dispensers set behind each test 
box. This was to reduce the effect of the dry mouth caused by scop-
olamine. The Y-maze was illuminated by a fluorescent ceiling light 
215 em. above the apparatus. 
Procedure. 
Each test session consisted of 10 trials. To begin the first 
trial, the rat was placed in an arm with a blank start box. The 
central door was raised, and the animal was allowed to choose between 
two arms that contained a matching pair of goal boxes (A1, A2, Figure 
2.1. ). The rat was deemed to have made a choice when both hind feet 
had been placed upon the choice arm, whereupon the guillotine door 
was lowered. The animal was rewarded with three reward pellets, 
whichever box had been selected. The animal was confined to the goal 
box (Al) for 20 seconds, during which time the other two boxes were 
removed and replaced. The central door was then raised, simultan-
eously revealing a familiar box, A2, in one arm and a novel box, Bl, 
in the other (Figure 2.1. ). The animal was rewarded with three food 
pellets if it chose the novel box Bl. These pellets were dispensed 
after the choice had been made. In this training condition the 
delay between the last experience of the sample stimulus, Al, and the 
choice between Bland A2 was close to '0' seconds (Figure 2.1. ). 
Following confinement in box B1 for 20 seconds, the second trial 
began. The central door was raised and the animal was allowed to 
choose between box B2 and a novel box C1 (Figure 2.1.). The novel 
box (C1) was positive. This sequence was repeated with new pairs of 
boxes for a total of 10 trials, during which selection of the novel 
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box was always rewarded. The position of the novel, and hence 
positive, box varied from right to left according to a pseudorandom 
schedule. The 50 pairs of test boxes ensured that any particular 
pair would be used on average every fifth day. The sequence of test 
boxes was revised after every 40 trials. 
If the animal made an incorrect choice, i.e~ chose the goal box 
that matched the start box, up to a maximum of four correction trials 
were run to encourage the animal to select the novel box. During 
these correction trials the goal boxes were arranged so that the 
novel, and hence positive, box was in the same arm, right or left, 
relative to the rat as in the test trial. 
The animals were trained until they reached a criterion of 40 
or more correct responses over five consecutive days (80% correct). 
They were then immediately transferred to the drug/delay regime. 
The rats received intraperitoneal injections of one of the following 
drugs dissolved in saline approximately 20 minutes before each 
session: 0.1 mg/kg physostigmine salicylate (Sigma Chemical Co.), 
0.01 mg/kg, 0.03 mg/kg and 0.06 mg/kg scopolamine hydrobromide, 0.03 
mg/kg scopolamine methylbromide (Sigma Chemical Co.), or saline. 
For all injections the dose was 1 ml/kg of rat. Unlike the pilot 
study, scopolamine hydrobromide was used instead of scopolamine hydro-
chloride. This form, which has a molecular weight approximately 6% 
heavier than the hydrochloride salt, provides a closer match with 
the scopolamine methylbromide control condition. 
In the first phase of the experiment each drug was tested not 
only under the training condition ('0' seconds), but also with a 60 
second retention delay imposed between the sample stimulus and the 
test. The delay was achieved by replacing the start box, after the 
animal had been in it for 20 seconds, by a blank, featureless box. 
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The animal was confined within this arm for 60 seconds before the 
central door was raised, revealing a novel goal box and one that 
matched the original start box. Thus in order to perform the task 
correctly the rat had to remember the start box for 60 seconds. 
Again the rat was rewarded for choosing the novel box, and incorrect 
choices were followed by up to a maximum of 4 correction trials. 
In the first phase there were thus 12 conditions in all, 2 delays 
and 6 drugs. The animals received 3 days (30 trials) at each of the 
12 conditions (36 sessions) in a balanced order, with no more than 
two 60 second delays, or two doses of scopolamine, occuring on con-
secutive days. 
After completion of the 36 test sessions, testing with both 0.03 
mg/kg scopolamine hydrobromide and 0.03 mg/kg scopolamine methyl-
bromide stopped as it was evident that these drug conditions had no 
discernable effect upon performance (see next Section). Each of the 
remaining drug conditions received an additional 20 trials, again at 
both '0' and 60 seconds, following a series of activity measures and 
control tests (Experiments Two and Three). This second phase of the 
experiment began approximately three months after completion of the 
initial 36 sessions, and within two weeks of completion of Experiment 
Three. 
2.1.4. Results and Discussion. 
In the first phase of the experiment (Figure 2.3. ) all drugs 
were tested over a total of 30 trials for each of the two delays 
( '0' seconds and 60 seconds). An analysis of variance revealed that 
there was no main effect of drug (F=1.92, df=5, 35), or delay (F=2.96, 
df=1, 7), although there was a significant interaction between drug 
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Abbreviations 
MSc, 0.03 mg/kg methyl scopolamine 
Phys, 0.1 mg/kg physostigmine 
Sal, saline 
Phys 
0·01 
MSc: 
•0·03 
0·06 
The remaining doses all refer to scopolamine. 
0 60 
DELAY LENGTH (SECONDS) 
(a) 
Mean performance on the nonmatching-to-sample task following 30 
trials at each of the five drug conditions and over the '0' and 60 
sec. retention intervals - First phase. 
and delay (F=3.24, df=5, 35, p<0.05). This interaction reflected 
the forgetting slope for the physostigmine condition (Figure 2.3. ). 
It was evident that neither 0.03 mg/kg scopolamine or 0.03 mg/kg 
methylscopolamine had any effect upon performance and these drugs 
received no further testing. 
The combined results from both phases of Experiment One are 
depicted in Figure 2.4. • An analysis of variance showed that both 
the drugs (F=9.22, df=3, 21, p<0.01) and the delays (F=5.81, df=1, 7, 
p<0.01) affected performance levels, and that there was a significant 
interaction between these factors (F=5.95, df=3,21, p<0.01). Further 
examination of the simple main effects revealed that there were no 
clear differences between the drug scores at 0 seconds (F=2.16, df= 
3, 21) but that significant differences were found after retention 
delays of 60 seconds (F=l0.72, df=3, 21, p<0.01). Subsequent analysis 
with the Newman-Keuls test revealed that the scores following inject-
ions of 0.06 mg/kg scopolamine were significantly lower than those of 
all other conditions, including saline (p<O.Ol). It is, however, 
important to note that despite these differences there was no signif-
icant interaction between saline and the 0.06 mg/kg scopolamine 
condition (Figure 2.4. ), and that the significant interaction in the 
overall analysis reflected the performance scores following physostig-
mine. This is borne out by the non-significant interaction when the 
saline scores were compared with the two scopolamine conditions (0.01 
and 0.06 mg/kg), and the physostigmine scores excluded (F=2.07, df= 
2, 14). In contrast, a comparison between just the saline and physo-
stigmine scores over the two delays retained the significant interact-
ion (F=5.57, df=1, 7, p<0.05). 
Although a higher dose of scopolamine was not used it was very 
evident from the pilot study that higher doses will impair performance 
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Abbreviations: Phys, 0.1 mg/kg physostigmine; Sal, saline. 
The remaining doses both refer to scopolamine. 
at the '0' second condition and so invalidate direct comparisons 
between forgetting curves. Indeed, the dose of 0.06 mg/kg scopolamine 
hydrobromide did lower the mean score at '0' seconds (Figure 2.3. 
and it was this fall, albeit non-significant, which ensured that 
there was no interaction between the 0.06 mg/kg scopolamine and saline 
conditions. This, combined with the lack of effect of 0.03 mg/kg 
scopolamine, indicates that there was no dose of scopolamine which 
would produce faster forgetting over the retention delay and not 
effect performance on the '0' second condition. 
There was evidence that physostigmine improved performance at 
the 60 second delay (Figure 2.4. ). This improvement was supported 
by the significant interaction between the forgetting slopes for 
saline and physostigmine (F=5.57, df=1, 7, p<0.05), although the 
physostigmine scores at 60 seconds did fail to differ significantly 
from the saline scores (Newman-Keuls 0.1>p>0.05). It should be noted 
that although Figure 2.4. suggests that injections of physostigmine 
actually resulted in better performance on the more difficult 60 
second condition, these scores did not differ significantly from 
those at '0' seconds. This may be contrasted with the clear fall in 
performance over the longer retention interval for the saline cond-
ition (F=5.43, df=l, 14, p<0.05). 
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Experiment Two. 
2.2.1. Introduction. 
Scopolamine methylbromide 0.03 mg/kg did not have a comparable 
effect on the object recognition task to any of the scopolamine doses 
used in Experiment One, and therefore did not act as an effective 
control measure for the peripheral effects of scopolamine on the 
animals' performance. In particular, the effects of scopolamine on 
motor activity cannot be discounted from the results of Experiment 
One, since signs of sluggishness were observed with doses of 0.06 
mg/kg scopolamine hydrobromide. 
It is possible that if an animal was less active in the Y maze 
after being injected with scopolamine (as was occasionally observed 
following the administration of 0.06 mg/kg scopolamine), then this 
would increase the total delay length at the choice point, and hence 
the memory requirement between seeing the start box and choosing the 
(novel) goal box, to over '0' or 60 seconds, respectively. Any 
reduction in performance on the task could therefore be accounted 
for as a function of increased delay length caused by decreased 
activity, rather than as an expression of a true memory decrement 
resulting from cholinergic blockade by scopolamine. In view of this, 
Experiment Two was designed to measure the effects on the overall 
activity of the animals of 0.01 mg/kg, 0.03 mg/kg and 0.06 mg/kg 
scopolamine hydrobromide. Physostigmine 0.1 mg/kg and scopolamine 
methylbromide 0.03 mg/kg were included for comparison purposes, with 
saline as the ultimate control condition. 
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2.2.2. Method. 
Subjects. 
The subjects were the same as for Experiment One. 
Apparatus. 
The activity boxes consisted of three cages similar in every 
respect to the animals' home cages. No food was provided in the 
activity boxes, although water was freely available. 
Three 0.5 volt photo-electric cells were fitted at equal dist-
ances along the outer length of each box, and were designed to be as 
unobtrusive as possible when viewed from inside the boxes. Each 
time a photocell beam was broken the signal was passed via an inter-
face to a BBC computer. The computer was programmed to record the 
number of beam breaks made by the rats over a period of one hour, 
analysed into five minute 'bins', and for each 'bin', to subdivide 
the total number of beam breaks into 'repetitive' breaks of just one 
beam, or of gross movement between two or more different beams. 
Procedure. 
This experiment began between 17 and 35 days after the complet-
ion of Experiment One. Prior to the commencement of the experiment, 
the rats were placed in the activity boxes (one rat per box) for one 
hour on each of two consecutive days, to allow them to become accust-
omed to the procedure. This was followed by two 'test free' days. 
On the second day, the rats which were to be tested were placed on 
the same deprivation diet as used in Experiment One. All animals 
were run on the activity schedule for six consecutive days, and at 
approximately the same time each day. Each rat was injected with one 
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of the following drugs - 0.01 mg/kg, 0.03 mg/kg or 0.06 mg/kg 
scopolamine hydrobromide; 0.03 mg/kg scopolamine methylbromide; 0.1 
mg/kg physostigmine, or saline, and was placed in an activity box 
(one rat per box) 15 minutes after the injection. The computer then 
recorded the 'repetitive' and gross movements made by each of the 
rats for a period of one hour (see Apparatus section). The drugs 
were administered according to a pseudorandom order, with no two rats 
receiving the same drug in the same one hour session. 
2.2.3. Results and Discussion. 
The results of this experiment are illustrated graphically in 
Figure 2.5. . The total beam break figures are comprised of the sum 
of the scores for gross movement and 'repetitive' movements. Figure 
2.5. indicates that the greatest level of activity occurred with 0.01 
mg/kg scopolamine hydrobromide. An analysis of variance based on 
total beam break scores, however, revealed that there were no signif-
icant differences between the activity scores for any of the six drug 
conditions (F<1). In other words, there was no main effect of drug 
on activity. 
These results indicate that scopolamine does not cause any 
greater inactivity than physostigmine, methylscopolamine, or saline. 
Decreased motor activity is not, however, the only effect of scopol-
amine. The decreased performance on the 60 second condition of 
Experiment One after injections of 0.06 mg/kg scopolamine may be due 
to any one (or more) of the drug's other actions (Hagan and Morris, 
1987). 
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Msc, 0.03 mg/kg methyl scopolamine. The remaining doses all refer 
to scopolamine. 
Experiment Three. 
2.3.1. Introduction. 
This control experiment examined which sensory modality the rats 
used to solve the delayed nonmatching-to-sample task, i.e., whether 
they had used visual, olfactory or tactile cues. The importance of 
these modalities was assessed by systematically varying the salience 
of the cues from the different sensory modalities. While it has 
been assumed that the rodents primarily make use of vision, it is 
possible that other senses may alternatively, or additionally be 
used. If this is so, the task may not be strictly comparable to a 
test of object recognition given to either monkeys or man since in 
both of these cases, the task will be solved on the basis of visual 
cues only. 
2.3.2. Method. 
Subjects. 
The subjects were the same as for Experiments One and Two. 
Apparatus. 
The apparatus was the same as that used in Experiment One, 
except that entirely new test boxes were used throughout. A control 
series (A) consisted of 21 new pairs of hardboard boxes of the same 
dimensions and specifications as Experiment One. Again, the boxes 
were in pairs which were made as similar as possible, but each pair 
was distinctive (Figure 2.6. ). Series B consisted of 21 pairs of 
boxes of the same specifications and dimensions as Series A except 
that the floors protruded only 2 em. (rather than 9 em.) towards the 
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Figure 2.6. 
© 
® 
Diagrammatic representation of the test sequence and stimuli used in 
Experiment Three. 
centre of the maze. This reduction meant that the rats could not 
receive any tactile cues before making a choice in the Y-maze. Like 
Series A these boxes contained distinctive objects and had different 
floor and wall coverings. Series C consisted of 21 pairs of boxes 
with different floor coverings. No other embellishments were used, 
and the interior of every box was painted a uniform grey. As a 
consequence visual, and probably olfactory cues were reduced while 
tactile cues were intact. It should, however, be noted that any 
change in tactile surface must inevitably produce some change in 
visual appearance. Series D consisted of 21 pairs of boxes in which 
the interiors were covered in photographic prints of various grey, 
black and white patterns. This ensured that the boxes could only 
be discriminated visually. Series E consisted of three pairs of 
completely blank, hardboard boxes (Figure 2.6. ). 
Procedure. 
Experiment Three began two months after the completion of the 
first 36 day drug session of Experiment One and between 33 and 58 days 
after the completion of Experiment Two. Due to the interval between 
this and Experiment One, the animals were given an additional 60 -
170 training trials until performance became stable. 
All of the control trials were run with '0' second delays, 
correction trials, and a pseudorandom sequence of left/right responses. 
Experiment Three was divided into four distinct stages which follow-
ed immediately after each other. In Stage One the animals received 
30 trials (three sessions) from each of series A, B or C in a mixed 
sequence. Only one series was used per session. In Stage Two the 
animals received six sessions with series C. During alternative 
sessions the task was run under very low lighting, the illumination 
76 
at the choice point in the centre of the Y-maze being 0.17 cd/mm 
(S.E.I. exposure photometer). In Stage Three the animals received 
30 trials with series D, 10 trials on each of three consecutive days. 
Finally, the animals performed 30 trials with series E (Stage Four). 
The blank boxes, which served as both start and goal boxes for every 
trial, were re-arranged after every trial. 
2.3.3. Results and Discussion. 
Figure 2.7. illustrates the mean performance of the animals 
during the various stages of the experiment and also indicates those 
sensory cues which were present. In Stage One the animals averaged 
24.0 correct responses (80%) on series A (the normal, control 
series), and 23.3 and 23.4 on series B and C respectively. All of 
these scores were significantly above the chance score of 15 (minimum 
t=l0.38, df=7, p<O.OOl), and there was no evidence of a difference 
between the three series (F<l). Clearly overall performance was 
unaffected when tactile cues were completely removed (series B) or 
when visual and olfactory cues were presumably reduced (series C). 
In Stage Two the animals averaged 23.0 correct responses in the 
light condition with series C, and 19.0 correct responses in the 
dark condition. Although both of these scores were significantly 
above chance (minimum t=7.57, df=7, p<O.OOl) the animals performed 
better in the light than in the dark (t=2.22, p<0.05). This differ-
ence in performance may reflect some partial use of visual cues in 
discriminating series C, although it is not possible to rule out the 
effects of a "generalisation decrement" (Hull, 1943; Mackintosh, 
1974). Of equal interest was the finding that the scores in the 
dark were still above chance. Thus the animals would appear to be 
77 
V) 
w 
en 
z 
0 
Q. 
Cl) 
w 
0:: 
.... 
u 
w 
0:: 
0:: 
0 
u 
..... 
z 
w 
u 
~ 
w 
Q. 
100 
90 
l S.E. 
A B C 
VS VS (VS) 
OLF (OLF) (OLF) 
TC TC 
c c 
(VS) 
(OLF) (OLF) 
TC TC 
D 
vs 
Figure 2.~ Mean percent correct on the control tests. 
The subscripts show the test series (see Figure 2. 6. 
Chance 
--
E 
and the 
sensory cues (OLF, olfaction; TC, touch; VS, vision) that were 
available to the animals. Symbols in parentheses indicate those 
sensory modalities for which cues may be present but are probably 
less than in the standard condition (series A). 
able to use olfactory or tactile cues. 
When the stimuli were restricted to two-dimensional visual 
patterns (Stage Three) the mean score was 18.4. This score was still 
significantly above chance (t=3.22, p<O.Ol) and was significantly 
better than the blank box (series E) control condition (t=l.95, 
p<0.05). The scores on this final condition (series E) did not differ 
from chance (mean=l6.0). These results showed that the animals 
could perform the task visually, even when the stimuli were only two-
dimensional. The relatively poor performance on series D (Figure 
2.7.) may partially reflect the use of stimuli which provide no depth 
cues, in contrast to the normal condition (series A). Support for 
this explanation comes from pilot experiments which have shown that 
rats can perform at up to 80% accuracy when the stimuli provide three-
dimensional cues but no olfactory cues. This was achieved by making 
the boxes and the distinctive stimuli out of the same material. 
In summary, it has been shown that the animals could perform the 
task when tactile (Stage One), visual (Stage Two) and finally tactile 
and olfactory (Stage Three) stimuli were removed. These findings 
strongly indicate that the rats were using cues from more than one 
sensory modality in order to perform the standard nonmatching task 
and hence could readily transfer when cues were systematically 
removed. It is not possible, however, to specify the relative value 
of these different cues in the standard condition from the results 
obtained in this experiment. 
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2.4. General Discussion. 
Experiment One examined the way in which the muscarinic blocker, 
scopolamine, disrupted a non-spatial test of working memory (non-
matching-to-sample). It was found that with a retention interval of 
60 seconds, a dose of 0.06 mg/kg scopolamine hydrobromide was 
sufficient to reduce performance. Although the results of Experiment 
Two suggest that this reduced performance cannot be attributed to 
the effects of scopolamine on activity, there is no evidence either 
that at this dose the drug increases the rate of forgetting on the 
object recognition task since no interaction was found between the 
0.06 mg/kg scopolamine and saline conditions (P. 70 ). 
The present study is not the first to show that scopolamine can 
impair tests of recognition memory in experimental animals. It 
should be noted, however, that the large majority of previous studies 
have used stimuli, either spatial or non-spatial, that are shown rep-
eatedly within a session (Bartus and Johnson, 1976; Dunnett, 1985; 
Heise and Hudson, 1985; Robuste1li et al., 1969). As a consequence 
such tests measure recency 'judgements. The only previous study to 
have used a large pool of stimuli was that of Aigner and Mishkin 
(1986), who showed that scopolamine impaired delayed nonmatching-to-
sample with trial unique stimuli in monkeys. The present study is 
in close accord with their findings. The control tests (Experiment 
Three), which sought to determine which sensory modality the rats 
were using to solve the recognition task, revealed that the rats were 
not relying exclusively on visual cues but were using information 
from a range of sensory modalities. This is therefore one respect 
in which the present task differs from similar tasks given to monkeys. 
The present study failed to find evidence that scopolamine can 
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promote faster forgetting at doses which do not disrupt the simplest 
version of the task. This finding contributes to the growing body 
of studies that have examined the effect of this drug upon rates of 
forgetting in rats. These studies, which have almost exclusively 
used tests of spatial working memory, have consistently shown that 
scopolamine does not selectively disrupt performance over longer 
retention intervals (Robustelli et al., 1969; Ksir, 1974; Heise et al., 
1976; Dunnett, 1985; Godding et al., 1982). The results from studies 
of primates are, however, less clear-cut, with some reports providing 
evidence of a selective interaction between drug and delay (Pontecorvo 
and Evans, 1985). 
The failure of scopolamine to show clear evidence of a specific 
effect upon retention in rats does not rule out an amnestic action 
for this drug; the drug could act upon some other aspect of memory. 
There is, however, clear evidence that this drug has multiple effects 
and a more parsimonious explanation of the actions of scopolamine 
may not require an effect on memory processes per se. For example, 
Warburton and Brown (1971) have shown that in rats doses of 0.063 
mg/kg scopolamine hydrobromide and above may affect attentional proc-
esses, while other studies have suggested an action upon sensory 
systems (Evans, 1975; Hagan and Morris, 1987; Spencer, Pontecorvo 
and Heise, 1985). 
In addition to its central actions, scopolamine has peripheral 
effects which may also influence the ability of animals to perform 
behavioural tasks. The drug methylscopolamine, which does not cross 
the blood-brain barrier, was therefore used to test the possible 
contribution of these peripheral effects. The pilot study had 
previously shown that the peripheral actions of scopolamine are not 
sufficient to impair performance at a low dose level. Although in 
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Experiment One the highest dose of scopolamine was not matched by a 
comparable dose of methylscopolamine, there is evidence from other 
studies of working memory in rats that doses of up to 0.5 mg/kg 
methylscopolamine do not reduce performance accuracy. For example, 
Beatty and Bierley (1985) found that 0.5 mg/kg scopolamine methyl-
bromide had no effect on either working memory or reference memory 
in a study of rats tested in a 12-arm radial maze. Dunnett (1985) 
and Heise and Hudson (1985) obtained similar results in tests of 
delayed matching-to-position and continuous delayed response, respect-
ively. This suggests that only doses of methylscopolamine in excess 
of 0.5 mg/kg may have any effect on performance accuracy. 
It has been shown that at certain doses physostigmine may 
improve performance on the delayed nonmatching-to-sample task in 
monkeys (Aigner and Mishkin, 1986). Although only one dose level 
was used in the present experiment there was evidence of an improve-
ment at the more difficult, 60 second condition. This is in general 
agreement with other studies of working memory in rats which have 
shown that physostigmine may improve performance (Dunnett, 1985; 
Squire, 1969), although in the present study the main effect of 
physostigmine was to flatten the forgetting slope, rather than to 
produce a general improvement at all conditions (Dunnett, 1985). 
As a consequence, it would be of particular interest to examine the 
effects of this drug over even longer retention intervals. 
Although the results of this chapter do not provide any stronger 
support for the use of physostigmine as a reliable therapeutic agent 
for dementia-related cognitive impairments than any other reports 
cited earlier, they do provide additional circumstantial evidence 
for a cholinergic role in such impairments. The results also contribute 
towards the belief that appropriate pharmacological manipulation of 
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the cholinergic system (perhaps in conjunction with other neurotrans-
mitter systems) may eventually be developed to alleviate some 
of the cognitive declines associated with Alzheimer's disease. 
Summary and Relevance to Alzheimer's Disease. 
Human studies have shown that scopolamine can disrupt tasks 
of recent memory (Crow and Grove-White, 1973; Drachman and Leavitt, 
1974; Sitarem et al., 1978), indicating that cholinergic disruption 
by muscarinic blockade can cause memory impairments which are 
comparable to those seen in Alzheimer's disease patients. The 
results of studies which have examined the effects of the cholin-
ergic agonist physostigmine in man also lend support to the cholinergic 
hypothesis of memory dysfunction (Davis et al., 1978). However, 
much of the psychopharmacological data derived from animal experi-
ments are confusing and contradictory, offering no clear support 
for the memory hypothesis. This is largely attributable to the 
effects scopolamine and physostigmine have on processes other 
than memory, such as attention, arousal and motivation: There 
is good evidence for cholinergic involvement in sensory and atten-
tional mechanisms, thus, in many experiments which demonstrate 
changes in learning rate, a sensory/attentional hypothesis may 
provide a parsimonious and viable alternative to a learning/memory 
hypothesis. Also, cholinergic intervention can result in overt 
motor effects, including stereotypy. In some cases, motor effects 
may interfere with task performance independently, or in addition 
to, effects upon learning, memory or retrieval. (It should be 
noted, however, that the mere observation of effects on movement 
or other processes does not preclude the possibility that these 
are secondary to a cognitive impairment). 
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In general, the results from animal studies question the 
notion that a cholinergic dysfunction is sufficient to produce 
the symptoms of Alzheimer's disease. The reader will recall 
that the neuropathology of this disease consists of cell loss 
in the nbM, the neocortex, and in limbic structures - particularly 
the hippocampus and amygdala. The sequence of these neuropathological 
changes is not known. The behavioural symptoms consist of recent 
memory impairments; language disorders - typically aphasia and 
agnosia; emotional changes and finally, total dementia. In terms 
of the cholinergic hypothesis that damage to the nbM causes global 
cholinergic dysfunction, the fact that anterograde amnesia is 
the first behavioural symptom to emerge in cases of Alzheimer's 
disease suggests that: 
(1) This function may be the most sensitive to the cholinergic 
abnormality. This is questionable, however, since decreasing 
CAT levels in experimental animals with drugs such as scopolamine 
does not cause a specific memory deficit. Furthermore, since 
loss of acetylcholine in the brain causes global damage rather 
than solely a deficit in memory, one would not necessarily expect 
to find a specific memory loss simply by blocking ACh with scopolamine. 
(2) The first neuropathologic structure to be diseased (the 
nbM, neocortex, and/or limbic system) has an important role in 
memory, hence producing a memory impairment if damaged. It 
has been assumed that the nbM may be the first structure to be 
damaged and hence be responsible for the amnesia. Recent evidence, 
however, indicates that this is not the case: It is more likely 
that damage to the nbM causes a general dementia rather than 
a specific memory impairment (Aigner et al., 1987). A comparison 
of Alzheimer's disease with encephalitis supports this notion, 
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and also suggests that damage to the limbic system (which is 
heavily interlinked with the cortex) is the most likely cause 
of memory loss. 
The same limbic and cortical structures are affected in 
both Alzheimer's disease and encephalitis; likewise emotional, 
language and memory deficits are evident in both disorders. 
Encephalitic patients, however, exhibit no evidence of dementia, and 
as far as is known, do not sustain either damage to the nbM or 
exhibit cholinergic dysfunctions. This implies that the recent memory 
impairments of encephalitic patients must be caused by damage 
to structures other than the nbM, and the same could also be 
true of the anterograde amnesia characteristic of Alzheimer's disease. 
There is a wealth of information suggesting that the limbic 
system has an important role in memory processes (Olton, 1982; Mishkin 
et al., 1982; Scoville and Milner, 1957; Squire and Zola-Morgan, 
1983). If this system was the first structure to be damaged 
in Alzheimer's disease, so causing recent memory impairments, this 
would be consistent with the finding that blocking ACh with scopolamine 
does not mimic the memory l~ss, as it is far more likely that 
damage to brain structures, rather than a cholinergic dysfunction, 
is responsible for the observed memory deficits. 
There is a need for a longitudinal study of Alzheimer's disease 
to be conducted, correlating progressive behavioural deterioration 
with the onset and sequence of neuropathological damage. In theory, 
this would be the simplest way of firmly establishing the functional 
contribution of damage to the nbM, cortex and limbic system to the 
memory loss and dementia characteristic of Alzheimer's disease. 
Despite the experimental disadvantages outlined above, the 
cholinergic hypothesis is still widely believed to be the most 
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viable explanation for the memory impairments characteristic of 
Alzheimer's disease, and so the psychopharmacological research continues. 
However, alternative procedures for the assessment of cholinergic 
involvement in the dementia and memory syndrome are beginning to 
emerge, for example, studies with the agent AF64A (ethylcholine 
aziridinium ion). This alternative will be discussed in Chapter 
Four. 
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CHAPTER THREE. ALUMINIUM STUDY. 
3.1.1. Introduction. 
While there is growing evidence linking the presence of 
aluminium with dementia it is necessary to determine whether this 
association is causal, or whether it is merely a secondary consequence 
of the disease. The aim of the experiments in this chapter was to 
examine the former alternative. It is already known that an intra-
cranial injection of aluminium salts can, in certain species, induce 
an experimental encephalopathy in which evidence of neurofibrillary 
degeneration is accompanied by deficits in learning and memory 
(Crapper and DeBoni, 1980; Crapper, 1976). Although this model has 
directed attention to the metal, .it has failed to resolve the vital 
question of whether aluminium is responsible for any of the symptoms 
of Alzheimer's disease. 
This failure reflects serious shortcomings in the experimental 
model. For example, it has been pointed out that only single filaments 
are produced in this experimental encephalopathy while double filaments 
are found in man (Wisniewski et al., 1976). Other important short-
comings concern the limited period following the injection of aluminium 
salts during which behavioural experiments can be carried out, and 
the restricted number of susceptible species. These limitations have 
narrowed the range of behavioural tasks which can be used. For 
example, many of these studies have been concerned with avoidance 
behaviour (Crapper and Dalton, 19731 , 19732 ; Petit et al., 1980) 
despite the lack of evidence that this class of task is sensitive to 
human dementia. Furthermore, interpretation of these animal studies 
is often complicated by the imminent onset of non-cognitive neurolog-
ical symptoms, such as ataxia, which may provide a purely physical 
limit to performance. 
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If the neuronal changes observed in Alzheimer's disease are due 
to the gradual accumulation of aluminium over many decades, then a 
more appropriate manipulation would be to examine the effects of 
chronic exposure to aluminium in animals. One simple method of 
doing this is to supplement the diet with aluminium salts. While 
the outcome of the few experiments which have attempted this have 
proved encouraging (Hinz and Dufort, 1983; Thorne et al., in press), 
a major difficulty is encountered in ensuring reliable uptake of 
aluminium to the brain. Recent epidemiological findings have, 
however, suggested a new way of solving this problem. The peculiar 
form of Parkinsonism dementia found in just a few sites (the island 
of Guam, the Kii Peninsular of Japan, and in southern West New 
Guinea) is restricted to regions containing high levels of aluminium 
in the water and soil, and prominent accumulations of aluminium have 
been found in the neurofibrillary tangle-bearing neurons of such 
patients. An additional common factor linking these three geograph-
ical regions is that they have unusually low levels of calcium and 
magnesium (Perl et al., 1982), and one interpretation is that it is 
this combination of high aluminium coupled with low calcium and 
magnesium which potentiates the uptake of aluminium and so produces 
the dementia. This possibility provides the conditions under which 
a chronic aluminium encephalopathy might be induced in animals. Such 
a model would have the clear advantage that the conditions under 
which aluminium enters the central nervous system match those in man. 
Furthermore, this technique may be amenable to a much wider range of 
species than the acute model, and the longer survival time provides 
the opportunity for much more extensive, sophisticated behavioural 
testing. This model also offers the opportunity to examine those 
variables which might effect aluminium uptake, e.g., age, calcium 
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balance, duration of exposure, form of aluminium, etc., and so help 
predict which members of the population are at most risk to this 
disease. It could also be used to test possible treatments designed 
to reduce levels of aluminium, e.g. 1 chelating agents. 
It is important to stress that behavioural testing is necessary 
in order to demonstrate whether increased levels of aluminium have 
any cognitive consequences and whether they are consistent with those 
observed in dementia. This is all the more important as the evidence 
from previous animal studies suggests that the pathological consequ-
ences of aluminium upon the brain may be similar, but not identical, 
to those observed in dementia, and the significance of this difference 
remains unknown. 
So, the aim of the present study was to develop a chronic 
aluminium encephalopathy in animals by the administration of a diet 
high in aluminium salts but low, or absent, in calcium and magnesium. 
The rat was used for the study since it has become the species of 
choice for most neuroscientific experiments, and also because there 
is evidence that rats and man may have a comparable resistance to 
the neurotoxic effects of aluminium (see Sections 1.4.4. and 1.4.12.). 
The experiments were carried out in collaboration with Dr. A. 
Sahgal at the M.R.C. Unit for Neuroendocrinology at Newcastle General 
Hospital. A large cohort of 80 infant P.V.G. rats was split between 
the M.R.C. Unit and Durham; 56 at Newcastle, 24 at Durham. Both 
centres administered an identical diet, the experimental animals 
receiving a high aluminium, low magnesium, calcium-free diet. There 
were, in addition, three control groups: One group was maintained 
on a low magnesium, calcium-free diet which was free from aluminium; 
one group was maintained on a normal diet; and the last group 
received a normal diet supplemented with aluminium. 
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The behavioural experiments concentrated on tests of memory, 
reflecting thecon sistent finding that memory deficits are the 
earliest and most frequent symptom of Alzheimer's disease. The 
animals were therefore tested on the non-spatial task of object 
recognition (nonmatching-to-sample) as used in Experiments One and 
Three of Chapter Two. As previously noted, one particular value of 
this task is that it closely matches tests of visual recognition 
which are known to be disrupted in Alzheimer's disease (Albert and 
Moss, 1984). An additional feature is that the task offers the 
opportunity to examine not only the rate of learning the task but 
also the rate of forgetting simuli used within a session (see 
Chapter Two). 
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Experiment One. 
3.1.2. Introduction. 
This experiment examined the effect of a diet high in aluminium 
(but low in magnesium and calcium-free) on performance of the delayed 
nonmatching-to-sample task in rats. The performance of the experim-
ental animals was compared to that of controls subject to a variety 
of dietary manipulations (see below), in order to provide a correlat-
ion between cognitive performance and aluminium uptake. It was also 
hoped to assess the extent to which a lack of dietary calcium might 
contribute to aluminium uptake. The doses of aluminium, magnesium 
and calcium used were the same in both this experiment and in a non-
matching-to-position study conducted at the M.R.C. Unit in Newcastle. 
It should be pointed out that this and the Newcastle experiment 
were not set out to be definitive studies with regard to the toxin 
hypothesis of Alzheimer's disease. Rather, they were conducted as 
pilot studies with the aim of assessing whether a chronic rodent 
model based on dietary manipulations of aluminium and calcium could 
be developed. If so, this model would then provide the basis of 
further experiments to assess the effect on aluminium uptake and 
memory loss of other variables e.g., form of aluminium, duration of 
exposure, precise calcium balance, treatment of aluminium neurotoxicity, 
etc •• Hence the present study should be regarded as no more than the 
first step towards an assessment of the precise role of aluminium in 
Alzheimer's disease. 
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3.1.3. Method. 
Subjects. 
The subjects were 24 male P.V.G. rats supplied by the M.R.C. 
Neuroendocrinology Unit at Newcastle General Hospital. The rats 
were housed in groups of three, and were each maintained on approx-
imately 15 g. of one of Diets A, B, C, or D, each day (see below 
for diet details). Distilled, de-ionised water was freely available 
in the home cage. The rats were aged approximately 6 weeks old when 
they were started on the diets, and were approximately 4,5 months 
old at the start of the experiment. They were kept on the diets 
throughout the behavioural testing and so were maintained on these 
diets for a total of 9.5 months. 
Apparatus. 
Calcium and magnesium-free diet, in a powdered form, was 
obtained from Labsure. Chemicals were then added to this basic diet 
to make four different diets, as follows: 
(1) Diet A consisted of basic diet; 1 g/kg magnesium trisilicate 
powder; 72 g/kg aluminium hydroxide powder; and 10 g/kg calcium 
chloride crystals. (+Aluminium, +Calcium). 
(2) Diet B consisted of basic diet; 1 g/kg magnesium trisilicate 
powder; and 72 g/kg aluminium hydroxide powder. (+Aluminium, 
-Calcium). 
(3) Diet C consisted of basic diet; 1 g/kg magnesium trisilicate 
powder; and 10 g/kg calcium chloride crystals. (-Aluminium, 
+Calcium). 
(4) Diet D consisted of basic diet and 1 g/kg magnesium trisilicate 
powder. (-Aluminium, -Calcium). 
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The calcium chloride crystals used in Diets A and C were 
dissolved in distilled water before being added to the basic diet. 
The required daily amount of each diet was measured out into plastic 
containers and mixed into a paste with distilled water. The 
magnesium trisilicate powder, aluminium hydroxide powder and calcium 
chloride crystals were all supplied by B.D.H .. 
Approximately 3.5 months after the start of the experiment, it 
was necessary to feed the animals on a substitute base diet for five 
weeks before being returned to the original Labsure base. The 
substitute base was made up of the following: Human grade cornflour 
(a pure source of starch); sodium chloride AnalR (Riedel-de Haen); 
potassium chloride AnalR (Koch-Light Ltd.); multivitamins (Bimeda); 
and caseine (Special Diet Services). Magnesium, aluminium and 
calcium were added to this substitute diet in the same proportions 
as before (see above) to form a comparable series of the four diets 
A, B, C and D. 
The maze apparatus was the same as that used in Experiment One, 
Chapter Two, except that 70 pairs of test boxes were used throughout. 
Water was not available in the maze, and the reward pellets used 
were 45 mg. calcium and magnesium deficient dustless pellets (Custom 
Biological Diets, Bioserv Inc.). 
Procedure. 
The rats were arbitrarily divided into four diet groups, 
comprising six rats per diet. The study was run blind, so that 
throughout testing, the experimenter did not know which diet label 
(A, B, C or D) corresponded to which particular diet constituents. 
The rats were given 2 - 3 weeks pretraining on the maze to 
familiarise them with the apparatus. Thereafter the nonmatching-to-
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sample procedure (including correction trials) was the same as that 
followed in Experiment One, Chapter Two, except that rather than 
being trained until they reached a criterion of 80% correct responses, 
all rats received a total of 400 acquisition trials on the nonmatch-
ing task, regardless of whether or not they actually reached the above 
criterion level within this time. The rats were tested in the same 
order each day, as follows; 3 each of Diets A, B, C, D, D, C, B, 
and A. 
Immediately after the completion of the 400 acquisition trials, 
the rats were transferred to the delay regime, which lasted for 9 
days. The delays of '0', 20 and 40 seconds were presented in a 
pseudorandom order, with 30 trials at each delay, and again, the 
procedure over this part of the experiment was the same as that 
followed in Experiment One, Chapter Two. 
Between three and five weeks after the completion of Experiment 
One and following completion of Experiment Two (P. 96 ), all of the 
animals were sacrificed. The rats were perfused intracardially with 
5% formal saline. The brains were subsequently blocked, embedded in 
wax (Paraplast) and cut into 10 pm. coronal sections. Every lOth 
section was mounted and stained with cresyl violet. 
93 
3.1.4. Results and Discussion. 
The results of the histological examination were negative: At 
least every third coronal section from all of the experimental 
animals was studied with light microscopy for evidence of cell loss 
and/or gliosis. Particular attention was given to the nbM, the 
hippocampal formation, the amygdala, and the neocortex. There was 
no evidence that any of the groups appeared unusual. 
Figure 3.1. illustrates the acquisition scores obtained over 
the first 400 trials of Experiment One. An analysis of variance which 
compared performance between the groups over the full block of 400 
trials revealed that there was a main effect of diet on the results 
(F=4.36, df=3, 15, p<0.05). Further examination of this main effect 
with the Newman-Keuls test identified that the scores obtained with 
Diet D (-Aluminium, -Calcium) were significantly higher than those 
of the other three conditions (p<0.05). In fact, it is interesting 
to note that five of the six rats on Diet D reached the criterion of 
80% correct responses (the criterion used in Experiment One, Chapter 
Two), within the 400 acquisition trials, compared to only 2 of the 
Diet B animals, 3 of the Diet A and none of the Diet C animals. It 
should be stressed, however, that there were no differences between 
the acquisition scores for Diets A, B or C. The main effect of diet 
noted above probably results from the relatively small number of 
subjects used in the experiment (i.e. n=6 in each diet group). 
The only other point to note with regard to the acquisition 
phase of Experiment One is that the P.V.G. rats appeared much slower 
to run round the Y-maze than the D.A. rats used in the experiments of 
Chapter Two. This could be a consequence of the dietary manipulations 
on the locomotor activity of the P.V.G.s, a point which will be 
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Figure 3.1. 
V) 
w 
V) 65 
z 
0 Q. 
V) 
w 
a::: 
tJ 60 
w 
a::: 
a::: 
0 
u 
..... 
z 55 
w 
u 
a::: 
w 
a.. 
z 
< 50 w 
~ 
Diet A o 
Diet B a 
Diet C o 
Chance 
------------ -~-- ---------.-- ----
100 200 300 400 
SUCCESSIVE BLOCKS OF 100 TRIALS 
Mean performance over the 400 acquisition trials of Experiment One. 
Diet A: +Aluminium, +Calcium 
Diet B: +Aluminium, -Calcium 
Diet C: -Aluminium, +Calcium 
Diet D: -Aluminium, -Calcium 
discussed further in Section 3.2 .. 
The results of the delay regime are illustrated graphically in 
Figure 3.2. . It should be noted that two rats, one from Diet B and 
one from Diet C, failed to complete all 9 days of the delay sequence 
and so their results are excluded. An analysis of variance revealed 
that there were no main effects of either diet (F=2.85, df=3, 18) or 
delay (F=l.04, df=2, 36), and that there was no significant interact-
ion between diet and delay (F<l), 
Previous studies using this paradigm have consistently shown that 
retention delays of 60 seconds produce reliable decrements in perform-
ance. The failure to find an effect of delay in the present study 
may reflect the shorter retention interval, but may also reflect the 
poor performance of individual animals on even the shortest delays. 
The failure to find a deleterious effect of supplementing 
aluminium to the diet is highlighted when the results of the two 
groups which received additional aluminium (A and B) are compared 
with the two groups which received no aluminium (C and D). An 
analysis of variance revealed no significant differences between A+B 
and C+D (F=3.63, 0.05>p<0.1 ). 
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Experiment Two. 
3.2.1. Introduction. 
This experiment was undertaken as a control for Experiment One, 
to provide some gauge of the effects of the various dietary manip-
ulations (outlined in 3.1.2.) on the motor activity of the animals. 
As previously mentioned (Section 3.1.4.), it was generally apparent 
that the P.V.G.s ran more slowly round the maze than the D.A.s. 
Although no immediately discernible differences in activity were 
noted between the four groups of P.V.G. rats in Experiment One, if 
there were differences or if one or two groups were particularly 
slow, this would make performance of the delayed nonmatching-to-
sample task more difficult and consequently reduce the number of 
correct choices made on the task. Since this could account for the 
subtle performance differences noted on the acquisition phase of 
Experiment One (Section 3.1.4.), it was considered appropriate to 
assess specifically whether or not there were any differences in 
locomotor activity between the four groups. 
It should be stressed that this experiment was strictly a control 
test, and was not intended to be a full assessment of the effects of 
aluminium on locomotion. Hence it was limited to only one test 
session per rat. It should also be pointed out that although examin-
ing rates of activity is a logical procedure to follow, the activity 
and reactions recorded in the activity boxes will be dissimilar to 
those occuring in the Y-maze since food motivation will affect 
activity in the maze. 
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3.2.2. Method. 
Subjects. 
The subjects were the same as for Experiment One, with the 
exception of two rats, both from the group maintained on Diet B 
(+Aluminium, -Calcium), which were excluded for health reasons. 
Apparatus. 
The apparatus was the same as that used in Experiment Two, 
Chapter Two, except that four boxes were used rather than three. 
Also, the computer was programmed to record the number of beam breaks 
occurring over a period of only half an hour (rather than a full 
hour), since it was apparent from a brief survey of the results of 
Experiment Two (Chapter Two) that the majority of the animals' 
movements occur within the first half-hour of being placed in the 
boxes. 
Procedure. 
This experiment began between one and three weeks after the 
completion of Experiment One. The rats were placed in the activity 
boxes (one rat per box) for 30 minutes each, and the computer recorded 
the gross and repetitive movements made by each of the rats over this 
period. The animals were tested in a pseudorandom order, according 
to diet, and were all tested once each over the course of a day. 
3.2.3. Results and Discussion. 
The results of this experiment are illustrated graphically in 
Figure 3.3. . An analysis of variance based on total beam break scores 
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Mean activity scores (gross movements, repetitive movements and 
total beam breaks) over a period of 30 minutes. 
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revealed that there were no significant differences between the 
activity scores for any of the four dietary groups. Thus, it is 
unlikely that changes in locomotor activity could account for the 
acquisition differences observed on the object recognition task. 
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3.3. General Discussion. 
On the basis of the toxin hypothesis of Alzheimer's disease, 
this part of the study was designed to assess the extent to which a 
diet high in aluminium (but low in magnesium and calcium-free) might 
be taken up by the rodent brain, and consequently what effects (if 
any) this might have on memory processes. With regard to behavioural 
testing, particular attention was given to tasks known to be sensit-
ive to the effects of damage to those regions which suffer the 
greatest pathology in cases of this disease, such as the hippocampus, 
amygdala, and basal nucleus of Meynert. Hence Durham tested rodents 
on a non-spatial task of object recognition, nonmatching-to-sample, 
and the M.R.C. Unit in Newcastle tested their rats on a spatial task 
of working memory, nonmatching-to-position, which was based on a 
task previously developed by Dunnett (1985). 
Experiment One did not provide any evidence that dietary 
manipulations of aluminium and calcium have an effect upon memory 
for the object recognition task. The results of the nonmatching-to-
position study conducted by the M.R.C. Unit similarly revealed that 
there were no significant differences between the various dietary 
groups tested on the task. 
The rats at Newcastle were first autoshaped on the nonmatching-
to-position task for 100 trials. The criterion was five consecutive, 
correct lever presses. There was no main effect of diet over this 
acquisition phase of the experiment. Four of Diet A, two of Diet C 
and one of the Diet D animals failed to learn the task, and the 
remaining animals were transferred to the delay regime: At '0' sees 
delay the criterion was 90% correct (or greater) on three consecut-
ive days, followed by a regime consisting of delays of up to 32 sees. 
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No group differences were detected at any delay when all four groups 
were compared (F<l), although the analysis was based on final group 
sizes of only four Diet A, six Diet B, two Diet C and ten Diet D, 
since many animals failed to complete the delay sequence. 
The brains from the experimental animals were subsequently 
analysed using a Perkin Elmer Atomic Absorption Graphite Furnace, but 
no group differences were found in tissue aluminium concentrations. 
Hence, we were unable to find any evidence that a diet high in 
aluminium salts could affect cognitive processes on either a spatial 
or non-spatial task of working memory. Additionally, Experiment Two 
failed to find any significant differences in activity levels between 
the four dietary groups. 
These negative results can best be explained on the basis of 
the histological data, which provided no evidence of a prominent 
accumulation of aluminium in the brains of those rats subjected to 
diets containing aluminium hydroxide (Diets A and B) in either Durham 
or Newcastle. Since the experimental methodology of this chapter was 
based on the hypothesis that accumulations of aluminium in the brain 
cause the learning and memory deficits associated with Alzheimer's 
disease (rather than the hypothesis that such accumulations are 
simply a secondary consequence of the dementia), it would be expected 
that memory impairments would not be in evidence if levels of alumin-
ium in the brain were not elevated. On the other hand, the present 
study failed to find any positive proof in favour of the hypothesis 
that brain aluminium causes cognitive deficits of the type seen in 
Alzheimer's disease, so the reason for the presence of aluminium in 
the brains of patients suffering from this disease remains an open 
question. 
It has been reported that at brain concentrations five or six 
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times that used in cats, aluminium injected rats do not show neuro-
fibrillary degeneration or more than a slight depression in behav-
ioural responses (King et al., 1975). In contrast, it has been 
demonstrated that the oral administration of aluminium to rats can 
result in behavioural change. For example, aluminium was found to be 
absorbed and deposited in the brain in a study in which it was admin-
istered in varying doses by intubation (Bowdler et al., 1979). High 
levels were associated with increased activity, decreased roto-rod 
performance, and increased sensitivity to flicker. Hinz and Dufort 
(1983) reported that aluminium administered to rats in the form of 
an aqueous solution of Amphojel (an antacid containing aluminium 
hydroxide) resulted in poor performance on an eight-arm radial maze 
relative both to the rats' pre-administration performance and to 
control behaviour. In a later study, Hinz (1983) both replicated and 
extended her earlier work, although unfortunately, Hinz and Dufort 
(1983) and Hinz (1983) were unable to perform an analysis of brain 
aluminium content. Without this analysis it is impossible to attribute 
the observed memory deficit to the effects of neural incorporation 
of aluminium. Thorne et al. (in press) attempted to remedy this 
defect: Adult Long-Evans rats were fed one of three doses of alumin-
ium hydroxide for 30 days:- 1513 mg Al/kg of body weight (low alum-
inium); 2697 mg Al/kg (moderate aluminium); or 3617 mg Al/kg (high 
aluminium), and were subsequently tested for open-field activity, 
passive avoidance learning, and active avoidance learning with 
reversal. Tissue aluminium concentrations were determined by graphite 
atomic absorption spectroscopy. 
Thorne et al. (in press) found no significant differences for 
whole brain comparisons of aluminium levels between the three exper-
imental groups and controls, although the means were in the right 
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direction: Controls, 6.01 ppm; low aluminium, 5.85 ppm; moderate 
aluminium, 6.49 ppm; high aluminium, 9.49 ppm. Significant differ-
ences were found, however, in hippocampal aluminium content, the high 
aluminium group having greater aluminium levels in the hippocampus 
than either the controls or moderate aluminium group. Higher doses 
of aluminium were associated with decreased activity in the open-
field tests, and in addition, elevated brain aluminium was correlated 
with relatively poor performance on the two avoidance tasks. 
Hence, the experiments of Bowdler et al. (1979) and Thorne et 
al. (in press) both demonstrate that oral administration of aluminium 
to rats can result in aluminium uptake by the brain. These, and the 
studies by Hinz and Dufort (1983) and Hinz (1983) have also shown 
that oral administration is effective in altering a variety of behav-
iours. 
In contrast to the above studies, the results of our experiments 
were rather disappointing. Although the exact reason for our negative 
results is not immediately discernible, there are a number of possible 
explanations for our lack of success in increasing aluminium uptake 
by the brain and producing an experimental encephalopathy. 
(1) The P.V.G. rats may have been too young at the start of the 
experiments, since they were only six weeks old when they were first 
placed on the diets. The rats used by Thorne et al. (in press) were 
placed in their diets at 8 months of age, and tested when they were 
9 months old - hence they were considerably older than our animals. 
It is postulated that infant rats (in comparison to adults) may have 
a resistance to the neurotoxic effects of aluminium in the same way 
as that reported in infant rabbits (Wisniewski et al., 1980; Petit 
et al., 1985). Also, given the late onset of Alzheimer's disease, 
it is a distinct possibility that old (or adult) rats may be more 
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sensitive to the effects of aluminium or may retain a higher proport-
ion of aluminium in their diet. For this reason, cohorts of old 
D.A. rats from Durham are being maintained on a high aluminium, 
calcium-free diet at the M.R.C. Unit in Newcastle. The rats were 
16.5 months old, on average, when they were first placed on the diet, 
and have currently been on this diet for 2.5 months. They will 
presently be subjected to behavioural testing of the sort described 
in this chapter (i.e., nonmatching-to-position) and the brains will 
be assayed for aluminium content. 
(2) Thorne et al. (in press) postulate that pre-treatment exposure 
to aluminium (i.e., from birth to 8 months of age) could account for 
the lack of clear differentiation between their groups in terms of 
brain aluminium content. Contamination from extraneous sources is 
not, however, a particularly likely explanation as to why there were 
no group differences between the P.V.G. rats in the present exper-
iment, since extreme care was taken (from weaning) to ensure that 
the rats could not come into contact with any easily controlled-for 
source of aluminium, e.g., contaminated food or reward pellets, tap 
water, aluminium-containing food or water dispensers. The only 
possible remaining source of aluminium contamination is room dust 
(Crapper et al., 1976), which would be unlikely to contribute greatly 
(on its own) to brain aluminium content. Nevertheless, contamin-
ation from an as yet unidentified source remains a possible explan-
ation for our negative results in respect of brain aluminium content. 
(3) Perhaps P.V.G. rats, as a strain, are particularly resistant to 
the effects of oral ingestion of aluminium. However, while there 
might be evidence of a species difference in resistance to the neuro-
toxic effects of aluminium (Petit, 1985) there is, as yet, no 
comparable evidence with regard to different strains of just one 
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species. Nevertheless, it might be interesting to repeat the 
experiments with O.A. rats (since they at least are able to learn 
the nonmatching-to-sample task far more quickly than the P.V.G.s) 
and/or with Long-Evans rats, since the latter have previously been 
shown to be sensitive to the oral ingestion of aluminium (Thorne et 
al., in press). 
(4) It is possible that 72 mg/kg was not a high enough dose of 
aluminium. The doses used by Thorne et al. (in press) far exceeded 
ours (see P.101 ), but even so, failed to produce large differences 
between control animals and the highest dose group in either brain 
aluminium content or behavioural effect, many of the comparisons 
made being non-significant. Although the dose of 72 mg/kg is reason-
able, i.e., not unreasonably high, it is a possibility that the 
experiments should be repeated following the administration of a diet 
with a much greater aluminium content. As mentioned in Section 1.4.4., 
humans may require 10 to 20 times the aluminium content of normal 
brains to exhibit an encephalopathy (see P.37 ). The same might 
also be true of rats - much greater levels of aluminium may need to 
be administered in order to produce any effect. 
(5) The P.V.G. rats used in the experiments at Durham and Newcastle 
were maintained on the various diets (outlined in 3.1.3.) for a 
total of 9.5 months, but we were unable to demonstrate either 
increased levels of aluminium in the brain, or any behavioural effects 
of aluminium administration, by the end of this period. In contrast, 
Thorne et al. (in press) kept their rats on diets containing aluminium 
for only 30 days and yet were able to report both increased uptake 
of aluminium and behavioural deficits. Hence, while it might be 
tempting to assume that the duration of exposure to aluminium was too 
short in the present study, this is perhaps the most unlikely 
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explanation for our non-significant results. 
(6) A combination of any two or more of the above might account for 
the lack of both elevated brain aluminium and behavioural deficits 
reported in this chapter. 
Having considered various fairly specific reasons which could 
explain why the experimental regime of the present study failed to 
find any neurobehavioural effects of aluminium administration we are 
left with only the wider implications, i.e.J that perhaps the ingestion 
of a diet high in aluminium but lacking in calcium is not an ideal 
model of aluminium encephalopathy. Perhaps the ALS-PD complex of 
Guam, the proposed origin of which provided the basis of the exper-
imental methodology of this chapter, is not mediated solely by high 
environmental levels of aluminium with correspondingly low levels of 
calcium and magnesium. Perhaps certain individuals within this 
environment are susceptible to aluminium neurotoxicity on the basis 
of some other, more primary factor, e.g., a malfunction of the blood-
brain barrier due to viral infection, genetic predisposition, or 
causes unknown. Or perhaps aluminium is merely a secondary marker 
of various disease states such as the ALS-PD complex, dialysis 
dementia, or Alzheimer's disease. There are many unanswered questions 
in this area of research, but in general, the results of previous 
studies investigating the oral ingestion of aluminium in rats are 
encouraging (Bowdler et al., 1979; Hinz, 1983; Hinz and Dufort, 1983; 
Thorne et al., in press), indicating that with perseverance, a rodent 
model of the learning and memeory deficits typical of Alzheimer's 
disease, and based on the toxin hypothesis, could be developed. 
As previously mentioned, future experiments at Durha~ and 
Newcastle will examine the effects of a diet high in aluminium but 
deficient in calcium in adult rats (as opposed to infants) and the 
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dose of aluminium will be increased. It is clear that under some 
circumstances aluminium is a neurotoxic substance, and that we need 
to know more about its mechanism of action before we can determine 
with certainty its role in disease, and the conditions in which it 
may be hazardous. 
Aluminium is certainly widespread in the environment. As 
mentioned in Chapter One (Section 1.4.2.), aluminium has a variety 
of sources, making it impossible to totally eliminate ingestion of 
this toxin. For instance, as far as food in concerned, some forms 
of sodium aluminium phosphate are used to release carbon dioxide gas 
from baking soda and leaven self-raising flours, cake mixes, pancake 
batters and frozen dough. At typical usage levels in these products, 
the final concentration of aluminium in each serving ranges between 
5 and 15 mg •• Alkaline aluminium phosphates are used as additives in 
processed cheeses, where each slice of processed cheese may contain 
50 mg. of aluminium (Ellinger, 1972). Aluminium salts such as sodium 
aluminium sulphate are used as firming agents in pickled vegetables 
and fruits, and aluminium silicates are commonly used as anticaking 
agents in salt, non-dairy creamers and other dry, powdered products 
where they may constitute up to 2% of the final powder mixture. 
Aluminium (as aluminium hydroxide) is present in many non-
prescription drugs such as the antacids and internal analgesics 
(buffered aspirin). These drugs are commonly consumed for the relief 
of minor gastric irritation or arthritic pain, and typical dosage 
levels can contain between 1 and 7 g. of aluminium per day. Gorsky 
et al. (1979) suggest that individuals ingesting a 1 g. dose of 
aluminium per day (as an aluminium hydroxide antacid) absorb 25% of 
the ingested aluminium into the body. Thus, the chronic consumption 
of aluminium in the form of drugs can account for a large cumulative 
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load of dietary aluminium. 
Aluminium is also a constituent of phosphate binding gels 
administered to patients with renal failure, antidiarrhoeal products, 
and may constitute up to 50% of some haemorrhoidal medications 
(Liane, 1985). 
The aluminium ion is a potent colloid-precipitating agent. With 
a certain precipitating power, for example 3000 ppm. sodium ion in 
an aqueous medium, this power can be doubled by adding only 22 ppm. 
calcium or 5 ppm. aluminium. These enormous changes in colloid 
stability can occur without noticeable change in specific conductance, 
a common parameter of water supplies (Riddick, 1968). For this 
reason, aluminium is being widely used to precipitate colloid 
turbidity in water purification. Water may, however, naturally 
contain large quantities of aluminium. It has been noted that 
aluminium is the most common metal on the surface of the earth, and 
is found in many clays and minerals. Surface water that has been 
acidified by acid rainfall dissolves substantial amounts of aluminium 
from the soil, which then accumulates in rivers, lakes, etc •• 
Underwood (1977) has suggested that a minimal daily intake of 
dietary aluminium may be about 22 mg .• In comparison to this value, 
data presented by Liane (1985) suggests that the use of aluminium 
cookware can contribute between 9 and 17% of the daily aluminium 
load in each serving of food. A report by Schlettwein-Gsell and 
Mommsen-Straub (1973) notes that the amount of aluminium in food 
cooked in aluminium pans is substantially elevated in acid dishes 
such as rhubarb or lemon. The use of aluminium pots to brew and 
reheat acidic beverages such as coffee is also likely to add signif-
icantly to daily aluminium intake. 
While some restrictions were introduced in 1979 limiting perm-
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issible levels of volatile aluminium compounds in air, there are no 
restrictions for soluble aluminium compounds in food or drugs 
(American Conference of Governmental Industrial Hygienists, 1979). 
In view of the widespread presence and use of aluminium, and the 
fact that it can be neurotoxic, we need to know more precisely its 
role in dementia, and (by controlled studies) if reducing aluminium 
ingestion does serve to reduce or eliminate the aluminium enceph-
alopathy. 
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CHAPTER FOUR. CONCLUSIONS AND POSSIBLE DIRECTIONS FOR 
FUTURE RESEARCH. 
Alzheimer's disease is characterised by progressive abnormalities 
of memory, behaviour and cognition. The brains of these patients 
show neurofibrillary tangles, senile plaques, and loss of specific 
populations of nerve cells. Neurochemical studies indicate that 
presynaptic cholinergic markers are markedly reduced in the cerebral 
cortex and hippocampus of affected individuals. This cholinergic 
deficiency appears to be due principally to a loss of neurons in the 
nucleus basalis of Meynert, a basal forebrain cholinergic system 
which projects directly to the hippocampus and neocortex. Loss of 
this cell population has also been implicated in other types of 
dementias showing features in common with Alzheimer's disease, for 
example, Down's syndrome (Price et al., 1982); and Parkinson's 
dementia (Betz and Goldstein, 1972). Additionally, the plaques and 
tangles of Alzheimer's disease have been found to contain aluminium 
(Perl and Brody, 1982; Edwardson et al., 1986). The above findings 
have led to proposals that either (1) cholinergic dysfunctions or 
(2) accumulations of aluminium in the brain are responsible for both 
the morphological characteristics and behavioural deficits of Alzheimer's 
disease. In general, it is the cholinergic hypothesis which has 
given rise to most research into the disease and also to the most 
attempts at therapy, although it is important to realise that many 
gaps remain in establishing a primary, causative role of the cholin-
ergic system in Alzheimer's disease. 
A major problem in the basic research and drug development for 
Alzheimer's disease is the lack of adequate animal models that can 
mimic all aspects of this disease. Generally, an animal model should 
allow for a more detailed evaluation of the neurochemical, neuro-
pathological, and behavioural sequelae of the primary cholinergic 
hypofunction suggested in this disorder. Such a model would be 
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instrumental in testing a wide variety of drugs, to determine whether 
they correct the cholinergic hypofunction and restore cognitive 
functions to normal. An animal model would obviously provide inform-
ation in studies that cannot readily be performed in humans, e.g., an 
analysis of neurotransmitter levels and metabolism in brain areas in 
vivo. Finally, an animal model that reproduces the specific neuronal 
deficits and cognitive dysfunctions of Alzheimer's disease may offer 
some clue about the underlying deficits of this disease state. 
The ideal model would be one that exhibits the same biochemical, 
behavioural, and histopathological abnormalities as the human disease 
state. However, there is at present no homologous animal model for 
Alzheimer's disease, since the aetiology of this disorder is still 
unknown. Partial success can therefore be achieved at this stage 
only with isomorphic models; that is, despite parallelism between 
the model and the human condition, the cause of the condition in the 
animal may be quite different from the cause in man. 
A number of experimental approaches or paradigms have been used 
that mimic different aspects of this progressive neurological 
disorder. These include: 
(1) Aged rodents and aged monkeys; 
(2) Scopolamine/aluminium treated experimental animals; 
(3) Excitotoxin lesioned rats or monkeys. 
Aged rodents and aged monkeys. 
Since Alzheimer's disease is a neurological disorder associated 
with aging, aged animals have been evaluated in many studies as 
possible animal models for age-related memory deficits and for 
Alzheimer's disease (Bartus et al., 1983). Aged rodents have been 
shown to suffer memory deficits on a variety of tasks (Bartus et al., 
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1983), the deficits being conceptually similar to the memory loss 
reported in humans. Further, drugs known to produce subtle improve-
ments in Alzheimer disease patients also improve the performance of 
aged rodents on tasks sensitive to age-related loss of memory, and 
similar findings have been reported for the aged monkey (Bartus et 
al., 1983). Also, neuritic plaques have been found in aged (23- 31 
years) rhesus monkeys (Struble et al., 1983). Hence both aged 
rodents and nonhuman primates are important models for testing hypo-
theses about human memory and cognitive impairments. The aged rodent 
or monkey model does, however, have several disadvantages. For 
example, since Alzheimer's disease is a neurologically progressive 
disease distinct from normal aging (Terry and Davies, 1983; Coyle et 
al., 19831 ), aged rodents or monkeys are not ideal animal models for 
this disorder (Gibson and Peterson, 1983). Moreover, aged rodents 
mimic to a certain degree the neurochemical changes associated with 
mormal aging, but not those presynaptic cholinergic dysfunctions 
(e.g.,decreased choline acetyltransferase activity) reported in 
Alzheimer's disease (Bartus et al., 1982). The high cost of old 
monkeys and even old rats in drug screening also severely restricts 
the practical use of these animals for research purposes. Finally, 
the poor health of aging animals and individual pharmacokinetic 
variabilities in drug absorption, metabolism and distribution, may 
sometimes yield statistically inconclusive data. 
Scopolamine/aluminium treated experimental animals. 
The literature pertaining to the use of scopolamine or aluminium 
treated experimental animals as potential models for Alzheimer's 
disease has been reviewed in Chapter One, and will not be repeated 
here. With regard to our work, the present study has not provided 
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any conclusive evidence in favour of either the cholinergic or the 
toxin hypothesis of Alzheimer's disease, although the experiments of 
Chapter Three (in particular) were only intended to be pilot studies 
on which to base more detailed research. On the other hand, several 
positive points can be made with regard to the experimental work of 
this Thesis: 
Principally, it has been shown that rodents are capable of 
learning a test of object recognition, nonmatching-to-sample. This 
is important, as such a task provides greater comparability to the 
non-spatial tasks typically given to assess learning and memory capac-
ities in primates (both human and nonhuman) than the more traditional 
tests usually given to rodents, e.g., passive/active avoidance. The 
object recognition task could now provide the behavioural basis for 
examining the effects on memory of lesions (e.g.,to the nbM); or the 
consequences of combining a diet high in aluminium salts with cholin-
ergic manipulations (see below); or for examining the validity of 
other animal models of Alzheimer's disease which have recently been 
proposed (e.g., the AF64A-treated animal- see P.114 ). 
Secondly, the similar effects of scopolamine and physostigmine 
upon delayed nonmatching-to-sample performance in rats and monkeys 
(Aigner and Mishkin, 1986) coupled with the effects of these drugs 
upon recognition in man (Davis and Mohs, 1982) suggests that equival-
ent manipulations in primates and rodents affect memory (and other, 
sensory processes) in the same way. The demonstration of related 
behavioural deficits and pharmacological responses in human and non-
human primates and rodents suggests that common etiologies may exist 
across a range of mammalian species, and supports the idea that 
rodent models for dementia-related memory loss can indeed be valuable. 
In general, the scopolamine treated animal provides a fairly 
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good model for evaluating the cognitive effects of pharmacological 
disruption of cholinergic function, though it lacks certain features 
necessary for studying the pathophysiology of Alzheimer's disease: 
Alzheimer's disease is a progressive, irreversible neurological disease 
whereas the effects induced by scopolamine in animals are reversible. 
Also, in Alzheimer's disease the cholinergic system is irreversibly 
compromised as a result of presynaptic degeneration of cholinergic 
neurons, without a significant decrease in postsynaptic muscarinic 
receptor binding (Vickroy et al., 1985). Therefore scopolamine, 
which causes mainly reversible blockade of postsynaptic muscarinic 
receptor binding, mimics only some features of Alzheimer's disease 
(Ridley et al., 1984). 
Aluminium treated experimental animal studies also raise a 
number of problems. For instance, the morphology of the neurofib-
rillary tangle induced by aluminium differs significantly from that 
of human Alzheimer-type tangles (Terry and Davies, 1983; Lee et al., 
1984). Also, the brain areas affected by aluminium in animals are 
significantly different from those areas affected in Alzheimer's 
disease (Wisniewski et al., 1980). Hence it appears that the 
induction by aluminium of neurofibrillary tangles in experimental 
animals, while an intriguing phenomenon definitely worth further 
exploration, is not a perfectly matching animal model for Alzheimer's 
disease. Moreover, its relevance to the etiology of this disorder 
is still an unsettled issue. 
Excitotoxin-lesioned rats and monkeys. 
A number of excitotoxins, e.g., kainic acid, ibotenic acid, and 
quino1inic acid, have been used for lesioning the nucleus basalis of 
Meynert, in order to induce in experimental animals cortical cholin-
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ergic lesions similar to those reported in Alzheimer's disease. A 
wealth of information regarding these types of lesions in the nucleus 
basalis has been accumulated in the last few years, including neuro-
chemical, histochemical, behavioural, and pharmacological observations 
(see Section 1.3.4.). The data described in Section 1.3.4. suggests 
that excitotoxin lesions can be useful in the production of animal 
models of the cortical cholinergic deficiency in Alzheimer's disease. 
However, several deficiencies in these models should be pointed out. 
Specifically, the excitotoxin-induced lesions do not produce the 
histopathological features characteristic of Alzheimer's disease such 
as neuritic plaques and neurofibrillary tangles (Terry and Davies, 
1983; Davies, 1979). Secondly, since these excitotoxins generally 
affect all neuronal perikarya regardless of neurotransmitter used, 
these lesions provide only limited information on the specific role 
of the cholinergic system in memory and learning deficits (Fisher and 
Hanin, 1986). Thirdly, excitotoxin-induced lesions of the nucleus 
basalis mimic only the cortical presynaptic cholinergic deficit of 
Alzheimer's disease; choline acetyltransferase activity in the 
hippocampus is not affected in excitotoxin-lesioned animals. 
For the reasons outlined above, neither aged animals, nor 
scopolamine/aluminium treated animals, or excitotoxin lesioned animals, 
provide totally adequate models on which to base an investigation of 
Alzheimer's disease. 
In spite of this, Fisher and Hanin (1986) have recently proposed 
the agent AF64A (ethylcholine aziridinium ion) as a potential tool in 
developing an animal model for Alzheimer's disease, and despite some 
caveats, data obtained to-date with the AF64A-treated animal are 
certainly encouraging. Cholinergic neurons possess a high affinity 
transport mechanism for choline, the HAChT, which is tightly linked 
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to ACh synthesis and appears to be highly concentrated on cholinergic 
neurons. AF64A is a chemical analog of choline which is selectively 
targeted toward the HAChT system because of its structural similarity 
to choline, but which, at the same time, is cytotoxic at the site of 
its accumulation in vivo. Hence AF64A induces a persistant central 
cholinergic hypofunction of presynaptic origin. 
Extensive neurochemical, electrophysiological, behavioural and 
histochemical studies have been conducted to evaluate the AF64A-
treated animal as a potential animal model for Alzheimer's disease. 
Most of these studies have been conducted with rats, and the following 
is a brief survey of the most pertinent results obtained to-date. 
Mantione et al. (1983) injected 2 nmo1. AF64A intracerebrally 
into the dorsal hippocampal area of rats, and found that ACh levels 
in this tissue were significantly lowered (-57%) within five days. 
This was paralleled by a significant decrease in the activity of 
HAChT (-77%) and ChAT (-58%), while choline levels and mAChr were 
unchanged in the same brain area. Moreover, serotonin uptake and 
noradrenaline levels were also unchanged. These results have been 
confirmed by other authors (Arst et al., 1983), though the consequences 
of AF64A administration into the nbM are equivocal: While some 
authors have reported decreased AChE staining in the nbM and a 
decrease in cortical activity of ChAT following administration of 
AF64A into the nbM (Arbogast and Kazlowski, 1984), others have 
reported appreciable non-selective damage in both the caudate putamen 
complex and nucleus basalis (McGurk and Butcher, 1985). The results 
obtained seem to depend on the dose of AF64A used, with higher doses 
causing correspondingly more non-selective damage. The optimal dose 
for administration into the nbM of rats has yet to be established. 
Behaviourally, rodents treated intracerebroventricularly (I.C.V.) 
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with AF64A have been reported to be impaired in retention of a step 
through passive avoidance task, and in radial arm maze performance 
(Walsh et al., 1984). Neurochemical changes were also evaluated in 
the same rats, with the finding that AF64A caused a persistent 
decrease in ACh levels in selected brain areas - notably the hippo-
campus and frontal cortex (Walsh et al., 1984). Behvioural observ-
ations were also made with AF64A (3 and 5 nmol. I.C.V.) in rats 
using the one-trial passive avoidance test (Brandeis et al., 1986). 
Interestingly, the AF64A-induced memory impairment on this task 
could be reversed by intraperitoneal pretreatment of the animals with 
physostigmine (0.06 mg/kg), thus indicating the potential use of 
this animal model in evaluating new drug treatments for Alzheimer's 
disease (Brandeis et al., 1986). 
The studies cited above demonstrate that AF64A mimics, at least 
qualitatively, the profound reduction of presynaptic cholinergic 
markers observed in most regions of the forebrain, and particularly 
the hippocampus and cortex, of Alzheimer disease patients (Terry and 
Davies, 1983). In addition, the persistent cholinergic deficiencies 
induced by AF64A in rats are paralleled by a long-term impairment of 
cognitive function in the affected animals. In Alzheimer's disease 
a decrease of presynaptic cholinergic markers is paralleled by 
chronic cognitive dysfunction (Terry and Davies, 1983), particularly 
anterograde amnesia. A similar behavioural pattern is observed in 
rats as a result of AF64A-induced cholinotoxicity (Walsh et al., 
1984; Brandeis et al., 1986). 
The AF64A animal model therefore has both neurochemical and 
behavioural similarities with Alzheimer's disease, and has two 
principal advantages over excitotoxin lesion studies. Firstly, 
AF64A effects the cholinergic system but leaves other neurotrans-
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-mitter systems intact, and secondly, AF64A administration decreases 
ChAT activity in the hippocampus in addition to mimicking the pre-
synaptic cholinergic deficit of Alzheimer's disease. The principal 
deficiency of this model (as in the excitotoxin lesion model) is 
that it does not mimic the histopathological characteristics (i.e., 
plaques and tangles) of the disease, or the accumulations of aluminium 
found in such features. Furthermore, the AF64A work is based on the 
cholinergic hypothesis that a cholinergic dysfunction (as a result of 
damage to the nbM) is responsible for the memory loss of Alzheimer's 
disease. As discussed in Section 2.4., it may be that nbM damage 
and/or the cholinergic dysfunction cause general dementia rather than 
a specific memory loss, and that damage to the limbic system is 
necessary to produce a recent memory impairment. The AF64A studies 
cited above are in accordance with this possibility:- they show that 
AF64A administration can cause a general dementia, but it is quest-
ionable whether the studies demonstrate that such treatment causes a 
specific deficit of recent memory. 
Nevertheless, from the literature to-date it can be deduced 
that AF64A, when used at appropriate concentrations, is a unique, 
selective and specific presynaptic cholinotoxin capable of inducing 
a long-term or even persistent cholinergic hypofunction in vivo. It 
could therefore prove to be a very useful model on which to base 
investigations into the cholinergic hypothesis of Alzheimer's disease, 
and for developing possible drug treatments for the disorder. 
The three principal (and interlinked) aims of developing an 
animal model of Alzheimer's disease are: 
(1) To establish the cause of the disorder; 
(2) to establish objective diagnostic criteria for the disease; 
(3) to develop an effective treatment for the disease. 
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Whilst much of the recent research into the neurochemical 
pathology of Alzheimer's disease has identified the involvement of 
particular neuronal systems which may ultimately improve the diagnosis 
and treatment of the disease, the original cause of the disease has 
not yet been identified. It is still not possible to attribute the 
cause of this disorder to either a malfunction of the cholinergic 
neurotransmitter system, or to exposure to an environmental toxin 
such as aluminium. However, the reader will recall that, in addition 
to the cholinergic and toxin hypotheses of Alzheimer's disease, 
which were examined in detail in the present study, four other 
hypotheses have been proposed to explain the cause of this disease. 
These are; the viral, vascular, abnormal protein and genetic hypotheses. 
While these hypotheses have, up to now, stimulated considerably less 
interest than the cholinergic or toxin hypotheses, they should not be 
discounted from a consideration of the cause of Alzheimer's disease. 
In particular, there is recent growing evidence that the disease may be 
caused by a genetic abnormality. 
Preliminary evidence in favour of a genetic component has come 
from the discovery of certain families with an unusually high 
incidence of Alzheimer's disease (Sjogren et al., 1952; Heston et al., 
1981), the pattern of inheritance being consistent with an autosomal 
dominant condition; and the higher concordance rate of the disorder 
in monozygotic twins than in dizygotic twins (Kallman and Sander, 
1949). The importance of genetic factors in Alzheimer's disease was 
also supported by the apparent relationship between this disease and 
Down's syndrome (Trisomy 21). Individuals over the age of 35 with 
Down's syndrome almost invariably develop the neuropathologic features 
of Alzheimer's disease including senile plaques, neurofibrillary 
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tangles, and neuronal loss in the basal forebrain cholinergic system 
(Casanova et al., 1985; Ellis et al., 1974; Haberland, 1969). In 
addition, many of these individuals also develop a dementing syndrome 
superimposed in the already present mental retardation. Moreover, 
Heston et al. (1981) demonstrated an increased number of individuals 
affected with Down's syndrome in the pedigrees of patients with 
Alzheimer's disease. As mentioned in Section 1.2.5., the link 
between Down's syndrome and Alzheimer's disease has recently been 
made much more explicit, as follows: 
Study of the proteins comprising the extracellular amyloid 
filaments deposited in the centres of senile plaques in Alzheimer 
disease brains has revealed that this disorder appears to involve a 
particular mutant protein that is processed and polymerised into 
amyloid filaments. Several laboratories have provided evidence that 
the principal protein component of plaque amyloid in Alzheimer's 
disease is a low molecular weight (4 - 5 kDa) hydrophobic protein 
(termed the ~-protein), whose composition shows no close homology to 
any known proteins (Selkoe et al,, 1986; Allsop et al., 1986). 
Various authors have reported the localisation of the ~-protein gene 
to chromosome 21 (Goldgaber et al., 1987; Tanzi et al., 1987). These 
important findings provide for the first time a direct explanation 
for the development of Alzheimer disease histopathological changes, 
particularly amyloid-bearing neuritic plaques, in virtually all 
patients with trisomy 21 surviving into adulthood. St. George-Hyslop 
et al. (1987) identified two tightly linked anonymous DNA markers 
(designated D2181/D21S11) on the proximal part of the long arm of 
chromosome 21, which show linkage to the gene responsible for familial 
(autosomal dominant) Alzheimer's disease in four families tested to-
date. Close linkage between the ~-protein gene and D21Sl/D21Sll has 
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also been established (Tanzi et al., 1987). Confirmation of these 
results in further families would point to DNA alterations in the 
region of chromosome 21 containing the ~-protein gene as the defect 
responsible for at least some inherited cases of Alzheimer's disease. 
The results summarised above suggest that genes on the long arm 
of chromosome 21, including a gene encoding a major amyloid precursor 
protein, play an important, perhaps primary role in the pathogenesis 
of Alzheimer's disease. However, the possibility that other proteins 
contribute to the amyloid deposits cannot be excluded, since the 
quantity of the ~-protein relative to other constituents in Alzheimer 
disease amyloid has not yet been determined. It is now important to 
determine the identification of other proteins associated with the 
~-protein and their possible role in amyloidogenesis. 
Selkoe et al. (1987) suggest that the amyloidogenic proteins 
associated with neuritic degeneration in Alzheimer disease brains are 
closely related to those deposited in animal brains during aging. 
Such a conclusion is consistent with recent molecular studies showing 
evolutionary conservation of the ~-protein gene (Goldgaber et al., 
1987; Tanzi et al., 1987). From this point of view, the severe, 
widespread expression of amyloidosis observed in Alzheimer's disease 
and Down's syndrome brains could represent an acceleration of an 
involutional process that occurs normally in the aged mammalian 
nervous system. Whether amyloid deposition in Alzheimer's disease 
involves specific mutations or increased gene dosage of amyloid 
precursor protein found in normal brain aging, and whether such 
putative changes are the site of the familial Alzheimer disease gene, 
remains to be seen. Although senile plaque neurites and neuronal 
cell bodies in old animals do not contain Alzheimer-type PHF, aged 
non-human primates provide a biochemically relevant model for a 
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principal feature of Alzheimer's disease:- cerebrovascular amyloidosis 
and senile plaque formation. 
Evidence for linkage of DNA markers on chromosome 21 to both 
the amyloid ~-protein gene and the autosomal dominant Alzheimer gene 
in some families fuels the hypothesis that an abnormality of DNA 
encoding the amyloid precursor protein, or perhaps more likely con-
trolling its expression, leads to greater amyloid deposition in patients 
with Alzheimer's disease and Down's syndrome than in normal aged 
humans. One of the many unanswered questions is whether the amyloid 
fibrils themselves can exert a neuritotoxic effect on the brain or 
whether other molecular changes associated with their formation or 
local processing are actually responsible for cortical damage. 
Although neuritic cytoskeletal changes may account in part for 
memory failure and other intellectual deficits of Alzheimer disease 
patients, understanding the cellular and molecular mechanisms of 
amyloid deposition and neuritic plaque formation appears more likely 
to lead to an elucidation of the etiology of Alzheimer's disease, 
thus warranting further research in this area. 
Whether indeed one solitary factor -genetic, cholinergic or 
environmental - is ultimately responsible for Alzheimer's disease, is 
not yet clear. It is possible that Alzheimer's disease may be caused 
by a combination of several factors rather than resulting from one 
discrete factor. Alternatively, the disease may simply have a number 
of different origins. Different investigators tend to see, or at 
least to focus on, six different sets of manifestations of Alzheimer's 
disease, and they collect six different sets of data. They then 
assume that Alzheimer's disease has its origin in genetics, protein 
accumulation, infection, a toxin, a neurochemical disturbance, or 
vascular insufficiency. Not many years ago different investigators 
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assumed that cancer is caused by substances in food, chemicals, 
environmental toxins, radiation or sunlight. All the investigators 
turned out to be correct - hence cancer can be the result of any one 
of the above individual causes. In time, it may emerge that the same 
is also true of Alzheimer's disease. 
I believe that it is possible that the cause of Alzheimer's 
disease may lie in the relationship between accumulations of aluminium 
and decreases in cholineacetyltransferase (CAT), and that this relat-
ionship should be investigated in depth (this relationship, in turn, 
may be directly or indirectly linked to genetic factors). As detailed 
in Section 1.3., dramatic decreases in CAT activity in the cortex and 
hippocampus of Alzheimer disease patients have been reported (Davies, 
1979), and other studies (Whitehouse et al., 1981; 1982) have indicated 
that the basal forebrain cholinergic neurons which innervate the 
cortex and hippocampus undergo a selective degeneration in Alzheimer's 
disease. The number of neurons in the basal nucleus of Meynert was 
decreased by 80% compared with age-matched non-demented controls, and 
some of the surviving neurons in this nucleus had neurofibrillary 
tangles (Whitehouse et al.; 1982). In view of this, and the finding 
that aluminium accumulates in the nuclei of tangle-bearing neurons, 
(Perl and Brody, 1980), a number of authors have postulated that there 
may be a link between CAT reductions and aluminium accumulations in 
neurofibrillary tangles (King, 1984; Yates, 1979). 
In animal studies, aluminium injections produced neurofibrillary 
tangles and reduced CAT activity in the spinal cord, "presumably due 
to the presence of tangles in the cholinergic motor neurons (Yates, 
1979). Miller and Levine (1974) conducted a cell culture experiment 
in which murine neuroblastoma cells developed tangles of 10 nm. 
filaments after six days in a medium to which aluminium had been 
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added. CAT activity declined by 36% in the aluminium-treated cells, 
compared with cells that were not exposed to added aluminium and did 
not develop tangles. In contrast, however, Hetnarski et al. (1980) 
reported that the activity of CAT in the brain may not be decreased 
following aluminium injections, and Wisniewski et al. (1980) notes 
that aluminium cannot be directly responsible for the inhibition of 
CAT, since 550 ug of Al/g of tissue (wet weight) produces only a 
20% inhibition of the enzyme activity. The brains of patients with 
Alzheimer's disease and animals with aluminium-induced tangles 
generally contain less than 5 ug Al/g wet weight. 
Johnson and Jope (1987) examined the effects of aluminium admin-
istration on presynaptic cholinergic markers (CAT activity, high-
affinity choline uptake and in vivo ACh and choline levels) in the 
hippocampus, cortex and striatum of rats. Aluminium was administered 
orally either as aluminium citrate (each rat consuming 5.6 mmol per 
day for one month), or as aluminium sulphate (each rat consuming 1.8 
mmol per day for one month), or I.C.V. as aluminium citrate (1 umol 
per rat). CAT activity, high-affinity choline uptake and ACh levels 
were not significantly affected by any of the above aluminium treat-
ments, though it is possible that the administration of aluminium in 
higher doses and/or for a longer period of time may alter these 
markers. However, dietary aluminium citrate reduced choline levels 
by approximately 30% in all three brain regions examined. Wurtman 
et al. (1985) suggest that reduced availability of choline may play 
an important role in the destruction of cholinergic nerve endings. 
Therefore, this effect of aluminium citrate warrants further invest-
igation. 
In general, it appears unlikely that the concentrations of 
aluminium present in the brains of patients with Alzheimer's dementia 
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cause the marked reduction (approximately 50%) in neocortical CAT 
activity via an acute, direct inhibition of enzyme activity. However, 
it is possible that prolonged exposure of neurons to aluminium may 
inhibit CAT activity indirectly via a reduction of choline levels. 
Johnson and Jope (1987) found that the most significant effect 
of the oral administration of aluminium sulphate was a 60% increase 
in cortical cyclic AMP levels, clearly demonstrating that dietary 
aluminium can alter metabolic processes in the brain. Since it has 
been suggested that abnormally high levels of cyclic AMP may induce 
neurofilaments or proteins associated with microtubules, and lead to 
abnormal structural re-arrangements of proteins (Theurkauf and Vallee, 
1983; Johnson and Jope, 1987), further studies are needed to determine 
if increased cyclic nucleotide levels induced by aluminium play a 
role in the development of dementia, senile plaques or neurofibrillary 
tangles. 
The search for the cause of Alzheimer's disease will undoubt-
edly become a high priority for biomedical research. Although some 
therapeutic strategies can be pursued without a major concern 
addressed to etiology - for example, the development of neurotrans-
mitter-specific therapies (Whitehouse et al., 1986)- progress toward 
the cure and prevention of Alzheimer's disease will require a greater 
understanding of its pathogenesis. In order to approach the goal of 
understanding the disease mechanism, certain steps need to be taken: 
(1) Clinical and pathologic descriptions of the disease and any 
subtypes that exist need to be as complete as possible. Prospective 
epidemiological studies need to be performed in which diagnosis is 
confirmed at autopsy. Several different pathologies occur in neurons 
(and perhaps non-CNS cells) of individuals afflicted with Alzheimer's 
disease. It is critical to identify which of these cellular alter-
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ations are non-specific and which are primarily characteristic of 
the disorder. 
(2) The structure of the proteins or other chemicals which are 
aggregated as insoluble fibrillary polymers in both amyloid and 
neurofibrillary tangles need to be described in more detail. 
Techniques for isolating these components from human brain tissue 
containing plaques and tangles have been greatly refined in the last 
few years (Selkoe, 1982). Knowledge of the chemical nature of these 
key pathological changes in Alzheimer's disease may well provide new 
insights into the nature and etiology of the disease. 
(3) We need to know more about the relation between the cholinergic 
deficits, degeneration of component neurons in the nbM system, and 
the variation in the symptomatic manifestations of the disease. The 
degenerative process may result in the appearance of neuronal-specific 
markers in the cerebro-spinal fluid or blood (though not for aluminium) 
or the development of specific immune responses that could serve as 
direct diagnostic tests for the disorder. Longitudinal studies are 
required, to correlate the neuropathology and cholinergic deficits 
with the behavioural symptomatology of the disease, at different 
stages in the course of this degenerative illness. 
(4) The significance of accumulations of aluminium salts in plaques 
and tangles needs to be determined - whether these accumulations are 
a cause or a consequence of neuronal loss has yet to be established. 
(5) The neuropsychological significance of the relationship between 
the appearance of multiple plaques and tangles and the development of 
the mental decline which characterises the disease needs to be 
explored. Furthermore, whether these pathological changes are a 
consequence of neuronal loss in key subcortical nuclei supplying 
axons to the cortex or whether they, in turn, induce subcortical 
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neuronal loss, has still to be determined. 
(6) The role of abnormal genes in Alzheimer's disease needs to be 
more fully defined. Specifically, the relationship between DNA 
markers on chromosome 21 to the amyloid ~-protein gene and to the 
autosomal dominant Alzheimer gene, and the etiological implications 
of this relationship, needs further exploration. 
(7) Comprehensive theories of the pathophysiology of the disease 
need to be constructed. Animal models should be developed to test 
aspects of these theories. Such theories need to consider how genes, 
the cholinergic system and the environment may interact to produce 
the disease, why certain populations of neurons are selectively 
affected, and why the disease occurs in the elderly. 
It is clear that further exploration of the possible causes of 
Alzheimer's disease will lead not only to understanding neurologic 
diseases but to fundamental advances in our understanding of neuro-
biology. However, for the time being we are left with the fact that 
the majority of patients are victims of a primary degenerative 
process. It is difficult to foresee rational therapy for these 
patients, particularly the more elderly ones. But unless some 
remediable cause is found, the professions have to face the inescap-
able problems of very large numbers of dements for whom the only 
present management is care, support and protection. With the 
increasing number of dements, the social and governmental implications 
are obvious. The present provisions in long-term psychiatric and 
geriatric departments are totally inadequate for patients, families, 
and indeed the clinicians involved. It seems likely that international 
governments will be forced by sheer weight of numbers to confront 
this important issue and to consider new projects for the proper 
care and protection of these subjects outside the conventional 
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hospital environment. 
Whatever the future holds it can be confidently stated that the 
last decade of research has opened up new vistas in our understanding 
of brain biochemistry in Alzheimer's disease. It is to be hoped 
that progress within the next decade will lead directly towards the 
ultimate goal of relieving the suffering imposed on individuals and 
society by the disease. 
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